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Abstract: 
 
Lassa fever virus is one of the most dangerous viruses of arenaviridae family, 
causing more than 500,000 infections per year in Africa. The fatality rate for 
hospitalized patients is as high as 20%. Due to the high fatality and lack of 
efficient licensed drugs and vaccines to treat and prevent, Lassa fever virus is 
classified as a Category A priority pathogen and biosafety level-4 agent by the 
Centers for Disease Control and Prevention of the USA. Cases were also found in 
the America and European countries, highlighting its potency to be a 
bioterrorism weapon.  
 
Like other areanaviruses, Lassa virus has developed a unique interferon 
suppression mechanism to evade from the host immune system, in which Lassa 
nucleoprotein plays the key role. To understand the LASV nucleoprotein 
functions, we tried to determine the first arenaviral nucleoprotein structure, 
LASV nucleoprotein. The LASV nucleoprotein (NP) was overexpressed and 
purified. The NP protein was crystallized and the structure was determined to 
1.80 Å resolution. The crystals belong to space group P3, with the unit cell 
parameters a = b = 177.16 Å, c = 56.49 Å, α = β = 90° and γ = 120°. The LASV NP 
structure contains two domains, which are not similar to any reported viral 
nucleoprotein structures. The N-terminal domain has a novel structure with a 
cavity, which we proposed for cap binding, and the C-terminus is a 3’-5’ 
ribonuclease, which is responsible for suppressing interferon production. To 
characterize the possible interaction between NP and other arenaviral protein, 
we also overexpressed and purified LASV Z. Interesting, both NP and Z proteins 
have two forms and the purified NP protein and monomeric Z protein bind RNA. 
 iv
It is surprising that only the oligomeric Z protein interacts with NP protein but 
the monomeric Z protein does not as determined by Isothermal Titration 
Calorimetry (ITC). Our studies have reported the first arenaviral nucleoprotein 
structure, revealed the novel mechanism for the cap binding and immune 
suppression, which set up a platform for development novel drugs and vaccines 
to treat deadly arenaviral infections. 
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1.1    Background information of Arenaviruse 
1.1.1    Arenaviruse epidemiology and evolution 
Arenaviridae viruses are a big group of enveloped and single-stranded RNA viruses, 
which have at least 22 members and can be divided into two subgroups the new world 
and the old world viruses according to the initial isolation places (Charrel et al., 2008). 
The old world group comprises seven viruses: Lymphocytic choriomeningitis virus 
(LCMV), Lassa virus (LASV), Mopeia virus, Mobala virus, Ippy virus, Morogoro 
virus and Kodoko virus, whereas the new world group has 15 viruses and is divided 
into three lineage: Clade A, B and C (Charrel, 2011). Lassa virus (LASV) is an old 
world virus that causes Lassa fever (LF) that is an endemic disease in West African 
countries like Nigeria, Guinea, Liberia, and Sierra Leone. Lassa fever virus infects 
100,000 to 500,000 people every year and about 15% to 20% hospitalized patients die 
from the infection (Khan et al., 2008). It was first found in 1969 when two missionary 
nurses died in Nigeria, and the virus was named after the town where the first cases 
were found.  
 
Lassa virus, along with other four new world arenaviruses Junin virus (JUNV), 
Machupo virus (MACV), Guanarito virus (GTOV) and Sabia virus (SABV) are the 
most well-known severe haemorrhagic fever (HF) causing arenaviruses. The cases 
also were reported in America and Europe (Rodrigo, 2011). The four new world 
arenaviruses that are all belong to the Clade B cause of Argentine, Bolivian, 
Venezuelan and Brazilian HF, respectively. New emerging arenaviruses that cause HF 
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like Chapare virus and Lujo virus are recently discovered and studied. These two 
viruses are found in Bolivia and Southern Africa, respectively. 
 
Furthermore, the prototypic arenaviruse LCMV which was first isolated in 1933 is 
considered to be a neglected human pathogen and is an important model to study 
persistent viral infection. LCMV is the causation of central nervous system disease, 
congentital malformations and has recently been reported to cause deaths in 
organ-transplant patients (Fischer, 2006; Palacios, 2008). Due to the high mortality 
and the lack efficient treatments for later infection patients, LAVS, JUNV, MACV, 
GTOV and SABV are categorized as diseases catalog A pathogens and biosafety 
level-4 agents by the National Institutes of Allergy and Infection of the USA (Illick et 
al., 2008).  
 
1.1.2    Transmission and Pathology 
Most arenaviruses are transmitted by certain closely related rodent species, in which 
the viruses could have very high titer in rodent bodies and do not result in any disease. 
The viral haemorrhagic fever (VHF) these viruses caused is characterized into several 
degrees along with shock syndrome in the final stage. Both the clinical and the 
experimental data show that the vascular endothelium participates in the transmission 
pathway. Lassa virus is typically transmitted by aerosolized virus particles via a 
rodent of the genus Mastomys natalensis (Table 1.1). Humans can be infected by 
direct exposure with the host or with food that has been contaminated with feces or 
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urine from infected mice. Lassa virus may also be spread between humans through 
direct contact or contact with contaminated urine, blood, feces and other bodily fluids 
(Fisher-Hoch, 1987). The incubation period is 7-18 days. The typical symptoms 
include fever, retrosternal pain, cough, vomiting, diarrhea, facial swelling and 
mucosal bleeding.  
 
The LASV viruses invade into dendritic cells, macrophages, hepatocytes and 
endothelial cells and replicate themselves by hijacking the cell machineries (Baize, et 
al 2009). Although the infection leads to little cellular damage, and is insufficient for 
organ failure like the hepatic failure, it is still causing patients to die as the anti-viral 
immune response is absent. The viral induced immunosuppression during infection is 
not well known, and the only antiviral drug, ribavirin, is most likely effective within 
the first week of infection. However, due to the LASV fever sympathies are very 
similar to other popular HF diseases in west African and lack efficient diagnostic 
methods, the LAVS infection patients most likely to miss the best time to be treated 
using ribavirin. Therefore, the ideal vaccine is supposed to based on a replication 
competent engineered and most likely to be preventive vaccine (Geisbert, et al 2005). 
Our research indicates the potential drug target by proclaiming the Lassa virus 
nucleoprotein structure and its role in the immune responses induced during LASV 
infection. 
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Table 1.1 Viral haemorrhagic fever caused by arenaviruses LASV, JUNV, MACV and 
filoviruses Ebola and Marburg virus (Table from Stefan Kunz, 2009). 
 
 
1.1.3    Genome structure of Arenaviruse 
Lassa virus like other arenaviruses is an enveloped virus with a bisegmented 
ambisense RNA genome that comprises a small RNA segment (S-RNA, 3.4 kb) and a 
large RNA segment (L-RNA, 7.2 kb). Each segment is reported to direct the synthesis 
of two viral genes in opposite orientation by ambisense coding strategy, separated by 
a non-coding intergenic region (IGR) with a hairpin structure. For Lassa virus, the 
S-RNA is always abundant and encodes the major structural elements – the internal 
nucleoprotein (NP, 64kDa) and the external precursor polypeptide (glycoprotein) GPC 
that is posttranslationally cleaved into two viral glycoproteins GPC1 (42 kDa) and 
GPC2 (38 kDa) by protease SKI-1/S1P. The L-RNA encodes a RNA-dependent RNA 
polymerase (L, 200 kDa) and a small RING finger protein (Z, 11 kDa) that binds zinc 
and acts as a matrix protein (Fig. 1.1). 
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Figure 1.1 The genomic organization of arenaviruses. The two segments encode four viral 
proteins NP, GPC, L and Z. 
 
There are 19 nucleotides at the 3’ and 5’ ends of both L and S genome segments are 
complementary to each other and highly conserved among arenaviruses. They are 
believed to be the binding sites of the viral polymerase. The nucleotide sequences of L 
and S IGR are different in most cases, but some IGRs on the same segment are also 
highly conserved. The IGR is the termination signal during the viral RNA 
transcription. The NP and L coding regions share the same transcription strategy by 
being transcribed into a genomic complementary mRNA from viral sense strand 3’ 
end to 5’end. The whole process happens right after the RNP is delivered into the 
cytoplasm of the infected host cells, and is initiated by the promoter located at 3’ end 
of each segment. There will be a cap structure at the 5’ end of the transcribed NP 
mRNA. Once the transcription of NP mRNA finished, the viral polymerase will then 
move across IGR to replicate a full length copy of antigenome RNA which will later 
serves as the template for the synthesis of GPC and Z mRNA (Fig. 1.2) (Emonet, 
2009). 
Genome Organization of Arenaviruses 
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Figure 1.2 The replication and transcription pathways of Arenaviruses. The two 
segments of arenaviurse use the ambisense coding strategy to replicate the viral genome and 
transcribe the four proteins with the priority of NP and L protein, and then GPC and Z 
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proteins (Figure was derived from Emonet, 2009). 
 
 
1.1.4    Receptors and the infection pathway 
The viral infection pathway is initiated by binding the receptors at cell surface. The 
Old world group arenaviruses like LASV and LCMV use α-dystroglycan (α-DG) as a 
primary cellular receptor while most of the New World group arenaviuses like JUNV, 
MACV, GTOV and SABV use transferrin receptor (TfR1) as the cellular cargo 
receptor. This makes a significant difference between the two groups (Rojek, 2008). 
Dystroglycan (DG) is encoded by a single gene, and is processed into two products 
α-dystroglycan and β-dystroglycan. The α-dystroglycan is a highly conserved and 
ubiquitously expressed cell surface receptor for proteins of the extracellular matrix 
and is associated with β-DG, which is a transmembrane protein linked to the 
cytoskeleton. These receptors are key elements during virus infection.  
 
LASV uses an unusual endocytotic pathway that is independent of clathrin, caveolin, 
dynamin and actin, while most of the new world enveloped viruses use clathrin coated 
pits for entry cell. The viruses are rapidly delivered to endosomes via vesicular 
trafficking once they entry the cell. The LASV was only mildly affected by dominant 
negative mutant of GTPase Rab5 which inhibits vesicular trafficking from the plasma 
membrane to the early endosome and was independent of Rab7 that is implicated in 
delivery from early to late endosomes. 
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1.1.5    Lassa NP  
The NP protein interacts with the viral RNA forming RNP, which is vital for the 
genomic RNA protection, the RNA transcription and replication. In addition, the NP 
protein of Lassa fever virus also is reported to interact with Z protein in vivo, and 
interact with host cell factors regulating human immune responses (Eichler et al., 
2004; Mahanty et al., 2003). There are also a serial of cell based functional assays 
designed for the anti-IFN activity of arenavirus NP protein. The studies in 
Martínez-Sobrido group showed that almost all the NP from Arenaviridae family 
(beside TCRV) can suppress the induction of type I interferon by inhibiting the 
translocation of interferon regulator factor 3 (IRF-3). The residue D389 from Lassa 
NP (corresponding to LMCV D382) is crucial for the anti-IFN activity, but there is no 
direct evidence to show why these amino acids are involved in this activity 
(Martínez-Sobrido, 2006; Martínez-Sobrido, 2007; Martínez-Sobrido, 2009). 
Therefore structural and biochemical studies on the NP and Z proteins are critical for 
us to understand the important biological processes and help us to find the novel 
targets for drug and vaccine development, which may help to treat and prevent the 
infections of lassa fever virus and other Arenaviruses. 
 
1.1.6     Lassa GPC, Z and L protein 
The pre-glycoprotein is cleaved by the cellular proprotein convertase subtilisin kexin 
isozyme-1/site-1 protease (SKI-1/S1P) in the endoplasmic reticulum to give two 
glycoproteins GP1 and GP2 as the final products, which are essential components of 
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the viral surface (Lenz, 2001). These proteins are essential for the virus to entry into 
host cells (Garbutt, 2004). The N-terminal GP1 is located at the top of the 
glycoprotein spike and is responsible for cell attachment that the GP1 binds to the 
α-dystroglycan receptor on the cell surface (Cao, 1998), while the C-terminal domain 
of GP2 is the transmembrane domain for fusing the viral particle into the cell. GP1 
and GP2 attached to each other noncovalently. The infection requires GP1 
dissociation from GP2 at low pH during entry of viral particles to endosome. The 
dissociation will expose fusogenic domains of GP2 and then trigger membrane 
penetration (Burns, 1993). 
 
Z protein is the driving force for Arenavirus budding (Perez, 2003;Strecker, 2003), 
and research showed that Z protein alone could form virus-like particles in host cells 
(Eichler, 2004). Z protein is abundant in viral particles and contains a zinc-binding 
RING motif. It also contains two proline-rich late domains, PPPY and PTAP, at the C 
terminus of Z protein. The two domains are involved in the fission of virus particles 
from the plasma membrane (Strecker, 2003). Although it is only 11 kD, Z protein has 
been reported to have multiple functions, regulating virus replication (Eichler, 2004), 
involving in transcription (Garcin, 1993) and interacting with host cellular proteins 
such as oncoprotein promyelocyte leukemia protein (PML) (Borden, 1998), the 
ribosomal protein P0 and the eukaryotic initiation factor 4E (Borden, 1998; Kentsis, 
2001; Volpon, 2010). However, how the Z protein interaction with the host proteins 
and what are the mechanisms are still elusive. 
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L protein is essential for viral replication and transcription. It mediates the synthesis 
of two viral RNA segments. The protein is split into three structural domains with the 
central domain harboring the RNA-dependent RNA polymerase (Fig. 1.3).  
 
N	terminal	
L1:	RNA	
endonuclease	 L2:	RdRp	
C	terminal	
Arenavirus	RNA	polymerase	L	protein	
1	 196	 1043	 1546	 2218	
L3	
 
Figure 1.3 Three functional domains of Arenavirus RNA polyermase L protein. L1 
domain is the endonuclease domain that may participate in the “cap-snatching” mechanism; 
L2 domain is the RNA dependent RNA polymerase; L3 is not currently well studied (data 
from Vieth, 2003 & pfam). 
 
Its oligomerization may be crucial for function like other negative strand RNA viruses 
(Smallwood, 2002; Smallwood, 2004; Sanchez, 2005; Zamoto-Niikura, 2010). Z 
protein binds L protein at two binding sites: N terminal residues between 160 and 290 
of the first domain and the RdRp (the second) domain, respectively. The first 200 
amino acids at the N terminal of L1 domain hypothetically contains an endonuclease 
corresponding to the N terminus of influenza virus PA which is known to have the 
endonuclease activity (Lelke, 2010). The structure of N terminal domain of LCMV L 
protein consists of 1 to 196 residues confirming that the L1 domain if an RNA 
endonuclease (Morin, 2010). Currently, the function of the second domain and the C 
terminal of the third domain is unknown, the structure of lassa virus L protein has not 
been determined, but many biochemical studies have shown its participation in the 
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“cap snatching” mechanism during viral transcription (Fodor, 2002; Vieth, 2003; Hara, 
2006) (see Appendix I.1 for the diagram of LASV virion). 
 
1.2    Cap-snatching  
Cap is an essential structure for mRNA transcription and translation, which chemical 
structure is shown in figure 1.4. The cap structure initiates the translation, protects the 
mRNA from exonucleases degradation, and it also regulates nuclear export along with 
the cap binding complex (CBC) for influenza viruses. In influenza A virus, once the 
mRNA is exported to cytoplasm, the translation factors eIF-4E and eIF-4G take place 
of the CBC, the translation initiates after ribosome recognize these factors. The cap 
that consists of a guanine nucleotide is connected with the mRNA via a 5’ to 5’ 
triphosphate bridge. The 7
th 
carbon on guanosine is methylated by methyl transferase, 
which leads the cap is abbreviated as m
7
G. 
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Figure 1.4 The 7-methylguanosine cap structure (colored in pink) that is kinked related 
to the nucleotides by the 5’ to 5’ triphosphate bond instead of the phosphodiester bond. 
 
Like influenza viruses and bunyaviruses, arenaviruses can’t synthesize mRNA cap 
themselves. Therefore, arenaviruses have to steal host mRNA caps for viral mRNA 
translation. Compared to influenza viruses and bunyaviruses cap-snatching, 
arenaviruses have two special features: firstly, the cap snatch occurs in the cytoplasm; 
secondly, the length of the cap template that the arenaviruses steal from host cells is 
normally 1 to 6 nt, but 8 to 16 nt for influenza viruses and bunyaviruses. 
 
1.2.1    Influenza A virus and the cap-snatching mechanism 
The most well studied cap-snatching mechanism in negative stranded RNA viruses is 
the initiation of viral mRNA transcription in influenza A virus (Bouloy et al. 1978; 
Beaton and Krug et al., 1981). These cap snatching viruses which include 
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arenaviruses, bunyaviruses,tenuiviruses and orthomyxoviruses are all from segmented 
negative stranded RNA virus. Unlike non- segmented negative stranded RNA viruses, 
these viruses are not able to synthesize the cap for its own viral mRNA, so they have 
to steal the cap either from the host nuclear pre-mRNA or the host cytoplasmic 
mRNA (Rey 2010). Influenza A viruses are segmented negative-stranded and 
ambisense RNA virus which belongs to the family of Orthomyxoviridae and is most 
well studied with this mechanism. Beside influenza A virus, other negative-stranded 
RNA viruses (like Germiston virus or TSWV) are found using the same transcription 
initiation strategy by using cytoplastic RNA cap as primers rather than nuclear RNA 
cap (Vialat and Bouloy,1992; Duijsings, 2001).  
 
The genome of Influenza A viruses contains eight RNA segments. These segments 
encode 11 viral elements: hemagglutinnin(HA), neuraminidase (NA), matrix 1 protein 
(M1), matrix 2 protein (M2), nucleoprotein (NP), non-structural protein 1(NSP1), 
non-structural protein 2(NS2), polymerase acidic protein (PA), polymerase basic 
protein 1 (PB1), polymerase basic protein 2 (PB2) and polymerase basic protein 1-F2 
(PB1-F2). The influenza A viral RNA polymerase complex which consist of three 
subunits PA, PB1and PB2 is responsible for replication and transcription of the viral 
RNA genome in the host nuclei. These three polymerases are the core factors of the 
virus, which locate at one end of the viral ribonucleoprotein (RNP) along with small 
amount of nuclear export protein (also called NS2). The viral RNAs are wrapped 
around the nucleoprotein (NP) (Samji, 2009).  
 15 
 
After the virus enters the host cell, the RNP complex that is made up of NP, PA, PB1 
and PB2 were released and then enter the host nuclei by using the nuclear localization 
signals (NLS) (Fig. 1.5). The viral negative sense strand RNAs were converted into 
positive sense strand RNA to serve as the template for viral RNA transcription. 
Although the full mechanism of the replication is unknown, many researches show 
that the RNA dependent RNA polymerase (RdRp) initiates RNA synthesis internally 
on the vrial RNA. 
 
A mature mRNA is supposed to have both a 5’ methylated cap and a 3’ poly (A) tail. 
However, influenza viruses do not encode any protein for cap synthesis. The 
hypothesis comes up with the cap-snatching mechanism which shows the viral RNA 
must have stolen the cap from host cellular mRNA. Both structural and biochemical 
studies later confirmed this idea. In the nuclei, the PB1 subunit holds the viral RNA 
within its centre, while the PB2 subunit is found to bind the 5’methylguanosine cap of 
the host pre-mRNA, then the PA subunit as an endonuclease to cleave 10- 13 
nucleotides from the cellular pre-mRNA that is used as the primers for viral mRNA 
synthesis. These capped, polyadenylated positive sense viral mRNA then are exported 
to the cytoplasm to translate into viral proteins. 
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Figure 1.5 Cap snatching mechanism in Influenza A virus. PA, PB1 and PB2 subunits 
form the heterotrimeric polymerase complex that carries the cap snatching mechanism. 
 
1.2.2    The polymerase subunits’ structures reveal the cap-snatching  
        mechanism 
1.2.2.1    The cap binding site on PB2 subunit 
Altough none of the full length structures of the complex subunits have been solved, 
the structural domains of half of the trimeric complex PA, PB1 and PB2 have been 
solved by either x-ray crystallography or NMR, which give us an overview of the 
polymerases’ function.  
 
The full length of PB2 subunit is insoluble, a new technology ESPRIT (Expression of 
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Soluble Protein by Random Incremental Truncation) provides soluble fragments of 
PB2 by screening almost 90, 000 fragments, which led to several domains structures 
(Yumerefendi, Tarendeau et al. 2010). The C-terminal domain of PB2 contains two 
independent domains: the domain that contains residue 627 and the nuclear 
localizaiton signal (NLS) domain (Fig. 1.6). The residue 627 is conserved as Glu and 
Lys in either avian viruses or human, the specific host range is unknown so far. Many 
studies refer that it’s the key factor for PB2-NP  interaction in host adaptation 
(Naffakh, 2000; Crescenzao-C, 2002; Labadie, 2007). A complex structure shows that 
the N-terminal domain of PB2 subunit (residues 1-37) tightly associated with the C 
terminal domain of PB1 subunit (residues 678-757) (sugiyama, 2009). 
 
Figure 1.6 The C terminal domain and N terminal domain of PB2. a, the C terminal 
domain of PB2 consists of two independent domains: the 627 domain (colored in blue) that 
contains residue Lys 627 (colored in red) that is crutial for host adaptation and the nuclear 
localization signal (NLS) domain (colored in green) (PDB code: 2VY6); b, the N terminal 
domain of PB2 subunit (colored in blue) in complex with C terminal domain of PB1 subunit 
(colored in green) (PDB code: 2ZTT). 
 
PB2 was considered to be the cap binding protein during the initiation of viral 
transcription since it was found that PB2 can recognize 5’ cap (Ulmanen, 1981), the 
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crystal structure of the central domain of PB2 (amino acid 318 to 483) in complex 
with cap analog m
7
GTP  later confirmed that PB2 holds the cap binding site 
(Guiligay, 2008). The residues that anchor the m
7
GTP with putative hydrogen bonds 
are K339, R355, E361, K376, N429 and H432. The aromatic sandwhich architechture 
of the typical cap binding proteins are accommodated by Tryptophan and Tryptophan 
for eIF4E (Marcotrigiano, 1997), Tyrosine and Tyrosine for cap binding complex 
(CBC) (Mazza, 2002), Tyrosine and Phenylalanine for vaccinia virus VP39 (Hodel, 
1998). The positvely charged m
7
G methylated base is recognized by PB2 aromatic 
residues Phe 404 and His 357 that hold the  π-electrons in the way of electrostatic 
interactions, the histidine is not observed in any well characterized cap binding 
proteins before (Fig. 1.7b). These two residues along with residues Phe 325, Phe 330 
and Phe 363 forms the novel hydrophobic region. The acidic residue E361 that is 
crucial for base specific recognition is also involved in triphosphate stabilization, the 
acidic cavity holds the interaction between the methylated m
7
G and the acidic acid 
Glu/Asp by both salt bridges and hydrogen bonds (Guilligay, 2008; Fechter, 2005). 
 
 
Figure 1.7 The central cap binding domain of PB2 in complex with cap analog m
7
GTP. a, 
the cap binding domain comprises 12 β sheets and 4 α helices (PDB code: 2VQZ); b, the 
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amino acids that interact with m
7
GTP. 
 
1.2.2.2    The endonuclease subunit PA and the PB1 subunit 
The structure of PB1 sunbunit has been poorly characterized, although it was 
previously considered to be the cap cleaving polymerase since it is predicted to have a 
classic polymerase fold in the center from its conserved motif (Poch, Sauvaget et al. 
1989). The C terminal PB1 interacts with N terminal domain of PB2 as previously 
descirbed, a short peptide on the N-terminal of PB1 was found in a complex with the 
C-terminal domain of PA subunit, these interactions are essential for the 250 KDa 
heterotrimeric polymerase complex to function properly and could be the good targets 
for anti viral drug design (Obayashi, Yoshida, 2008) (Fig. 1.8).  
          
Figure 1.8 The complex structure of N terminus of PB1 (residues 1-81) (colored in light 
blue) and C terminus of PA (colored in orange) (PDB code: 3EBJ). 
 
The endonuclease PA subunit consists of two domains: C-terminal domain and N 
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terminal domain. The N-terminal domain of PA subunit has an endonuclease active 
site which is similar to the nuclease PD-(D/E) XK family. It suggests that the PA 
subunit holds the function of cleaving host pre-mRNA  during cap-snatching rather 
than PB1 subunit, and the activity is Mg
2+
 dependent (Fig. 1.9). Although the native 
crystal structure did not provide any evidence on how PA subunit cleaves capped 
mRNA, the three residues P107, D108, E119 out of the six residues (plus E80, L106 
and H41) that coordinate the Mg
2+
 ion align very well with many endonucleases, 
which suggests that the (P)DXN(D/E)XK motif of PA N-terminal subunit comprises 
the endonuclease activity (Yuan,2009; Dias, 2009). 
                               
E80	 H41	
E106	
P107	
D108	
E119	
Mg	
a	 b	
 
Figure 1.9 The structure of N-terminal domain of PA that reveals the endonuclease 
active site. Mg
2+ 
is colored in blue. The residues around the active site areP107, D108, E80, 
E106, E119 and H41. 
 
 The similar polymerase endonuclease function exits in almost all known negative 
strand segements viruses like arenaviruses (2 segments), bunyaviruses (3 segments), 
tenuiviruses (4-6 segments) and orthomyxoviruses (6-8 segments influenza A virus) 
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by sequence ananlysis (Fig. 1.10). Recently, strucutural evidences of an endonuclease 
of the N terminal domain of L protein from both La crosse orthobunyavirus and 
Lymphocytic Choriomeningitis virus are present (Reguera, 2010; Morin, 2010).  
 
 
Figure 1.10 Sequence alignment of different negative strand segment viruses. The 
endonulease domains which are shown in red are all located at N terminus of L protein in 
each virus beside in influenza A virus it is located at the N termimus of PA subunit. The blue 
region is the conserved polymerase domain (figure from Reguera, 2010) 
 
1.3    Interferons and immune response 
Lassa virus nucleoprotein shows an immune suppression function by suppressing type 
I interferon induction. In this chapter, the role of interferons in immune response and 
nucleoproteins in both Old world and New World representative arenaviruses which 
hold the same function will be given as basic information.  
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1.3.1    The two immune systems and interferons classification 
Immune system is a protecting system for an organism to detect and kill pathogen or 
tumor cells. Immune system comprises two types, innate immune system and adaptive 
immune system. Innate immune system acts rapidly upon infection in a non-specific 
manner while adaptive immune system provides specialized long lasting defences. 
Normally in higher mammals, the adaptive immune system is very well developed to 
generate specific antibodies and T cells to either destroy the infected cell or disable 
the virus function. But this process can take days or weeks for efficient development, 
so the organism needs to have initial sensors to detect viral infection at early stage.  
Interferons (IFN) play an important role in innate immune responses and influence 
some adaptive immune responses, the antiviral activity of IFN was first found in 1957 
by Isaacs and Lindenmann (Isaacs, 1957). IFNs have three major biological functions: 
antiviral activity, antitumour activity and immunomodulatory effects. IFN is classified 
into two types, Type I IFN and Type II IFN. The discovery of type I, type II 
interferons and IFN-like cytokines along with their receptors gave us an idea of the 
innate and adaptive immune response. Type I IFN consists of 7 classes: IFN-α, IFN-β, 
IFN-δ, IFN-ε, IFN-κ, IFN-τ, IFN-ω. IFN-α has 13 subspecies whereas the other 6 
Type I IFN have only one subspecies. Type II IFN has only IFN-γ. Besides these 
two types, four IFN-like cytokines have been found: limitin, interleukin-28A 
(IL-28A), IL-28B and IL-29 (Pestka, 2004). Recently, the IL-28A, IL-28B and IL-29 
are also classified as Type III IFNλ1，IFNλ2 and IFNλ3, respectively (Kotenko, 2003). 
All the proteins above can be found in humans except IFN-δ, IFN-τ and limitin (only 
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in mice). The three types of IFN I, II and III use different signal transduction 
pathways and their genes are encoded on human chromosome 9, 12 and 19, 
respectively (Pestka, 2004). 
 
1.3.2    Type I IFN expression and signal transduction pathway  
Various NP proteins from Arenaviridae family have been documented for their 
interferon inhibition function (Martines-Sobrido, 2006; Martines-Sobrido, 2007). 
Since almost all the NPs inhibit induction of Type I IFN with a notable except of 
Tacaribe virus. A brief introduction of Type I IFN induction process, signal 
transduction pathway will be given. 
 
1.3.2.1    Induction of IFN expression 
The host pattern-recognition receptors (PRRs) which are found in innate immune cells 
can recognize the pathogen-associated molecular patterns (PAMPs) like viral genomic 
single strand RNA, double strand RNA and DNA to serve as initial detection of viral 
infection. Toll-like receptors (TLRs) and retinoic acid inducible gene I (RIG-I) like 
receptors (RLRs) are the two main classes of PRRs which can activate the antiviral 
response including induction of Type I IFNs and Inflammatory cytokines. TLRs are 
transmembrane proteins that can detect virus on cell surface or within endosomes, 
whereas RLRs function in cytoplasm as viral sensors. There are three known 
members of the RLRs family: RIG-1, melanoma differentiation-associated gene 5 
(MDA5) and laboratory of genetics and physiology-2 (LGP2). Both RIG-I and 
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MDA-5 contain a DExD/H box helicase domain that will recognize viral RNAs, the 
difference is that RIG-I preferentially recognizes 5’ end phosphorylated single strand 
RNA and double stand RNA while MDA-5 binds 5’non-phophorylated long dsRNA. 
Because of this difference, RIG-1 and MDA-5 are responsible for recognizing distinct 
types of viruses (McCartney, 2009). 
 
Type I IFN-α and IFN-β that were identified as a prototype of many cytokine families. 
IFN- α and IFN-β had not been reported until 1978 (Berthold, 1978; Rubinstein, 1978; 
Pestka, 2007). Although the main function of type I IFNα/β is on generating an 
antiviral state, more evidences have shown that they are also involved in other actions 
like anti tumor activities and the control of cell growth. Expression of type I IFN is 
regulated at transcriptional level by transcription factors including NF-κB, 
ATF2-c-Jun, interferon-regulatory factor 3 (IRF3) and IRF7.   
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Figure 1.11 The induction pathway of type I IFN. Viruses infect cells and produce 
different PAMPs molecules. The cellular receptors can detect different PAMPs and trigger 
different pathways to produce IFNs, and IFNs can activate different interferon stimulation 
proteins, which can control the viral infections. 
 
Nucleoprotein from arenavirus lymphocytic choriomeningitis virus (LCMV) has been 
documented for its inhibition of type I interferon production by blocking IRF-3 
(Martinez-Sobrido, 2007). IRF-3 is located in cytoplasm in an inactive state, it will be 
activated by phosphorylation. The C-terminal domain of IRF-3 is phosphorylated by 
kinases IKK-ε and TBK-1to induce IRF-3 dimerization, then IRF-3 is translocated to 
nuclei, form a complex CREB-binding protein CBP/p300 which later initiates IFN-β 
transcription (Yoneyama, 1998). The two kinases are activated by RIG-1, MDA-5, or 
probably some Toll-like receptors (TLRs) via IPS-1. Unlike IRF-3, IRF-7 needs to be 
induced by IFN since its expression level is low in most cells. There are also 
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transcription factors ATF2-c-Jun (AP-1) and NF-κB that are activated by the PKR 
pathway, which are promoted as a more general stress response. All these factors 
together can up-regulate IFN-β mRNA synthesis. IRF-3 is thought to be responsible 
for initiating IFN-β induction rather than IFN-α, whereas IRF-7 can activate both 
IFN-α and IFN-β induction. Homodimer IRF-7 or heterodimer IRF-3 and IRF-7 play 
the major role for induction of IFNα/β rather than the homodimer IRF-3 alone, which 
means IRF-3 has little contribution without IRF-7 (Honda, 2005a; Honda 2005b) (Fig. 
1.11). 
 
1.3.2.2 Type I IFN signal transduction pathway 
The IFN and IFN like molecules use the Jak-Stat signal transduction pathway. For 
type I IFN, the receptor consists of two subunits: IFN-αR1and IFN-αR2 that are 
associated with janus protein tyrosine kinases (Jak PTKs) Tyk2 and Jak1, respectively 
(Uze, 1990). The initiation of type I IFN signal transduction is the activation of the 
receptor associated Jak PTKs. These kinases will then phosphorylated their 
downstream substrates Stat1 and Stat2 that are the two members of the signal 
transducers and activators of transcription (Stats) family. Although Stat1 and Stat2 are 
the two main factors used in IFN-α and IFN-β signal pathway, Stat3, Stat4, Stat5 and 
Stat6 also have been reported in the same pathway under diverse conditions. Stat 3 
and Stat5 are reported to be pre-associated with Stat1. The activation of Stat4 and 
Stat6 are specialized to certain cell types like endothelial cells or lymphoid origin 
cells (Fasler-Kan, 1998; Torpey, 2004). 
 27 
            
 
Figure 1.12 The complex of Type I IFN receptors (picture modified from Pestka, 2004).  
Phosphorylated Stat1 and Stat2 dimerize and recruit a non-phosphorylated factor 
IRF-9 to form a heterotrimer ISG factor 3 (ISGF3) that is translocated into nuclei, 
then initiate the transcription of numerous ISGs by binding IFN-stimulated response 
elements (ISRE). These antiviral ISGs proteins can limit the virus replication in cells. 
In influenza viruses, the most well studied antiviral proteins are: dsRNA-activated 
protein kinase PKR, 2’-5’oligoadenylate synthetase (OAS), myxovirus resistance 
gene A (MxA), viperin and IFN-stimulated gene ISG15. Besides this classic ISGF3 
complex inducing signal pathway, there are also several complex receptors that 
induced by type I IFN that will not be discussed further (Fig. 1.12). 
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1.3.3    Virus evasion from IFN system 
Human cells have different receptors to detect viral infections, triggering different 
pathways to produce interferons, which are the first line for defending viral infections. 
However, different RNA viruses have developed different strategies to evade human 
immune responses, for examples, influenza A virus, human herpesvirus and 
arenavirus whose evasion pathways are described in the following paragraphs. 
 
1.3.3.1    Influenza A virus 
Type I IFN has been reported for its critical role in responding to the influenza A 
virus infection. Influenza A virus counteracts with the host defence system by 
primarily targeting either the IFN induction or signalling cascades. The non-structural 
protein 1(NSP1) of influenza A virus limits innate immune responses with several 
strategies: NS1 protein limits RIG-I mediated IFN-β promoter by inhibiting the 
activation and translocation of the transcription factors IRF-2, NF-κB and 
ATF2-c-Jun, which prevents PAMPs from being detected by the immune defense 
system; NS1 regulates host cell gene expression by binding cleavage and 
polyadenylation specificity factor (CPSF30) to prevent it from processing 3’ end of 
pre-mRNA into polyadenylated mature mRNA; influenza A virus replicates in nuclei, 
which prevent the RNA PAMP from being detected by sensors in cytoplasm; NS1 
also inhibits antiviral proteins like 2’-5’ OAS/RNase L and TRIM25/RIG-I mediated 
IFN production.  
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1.3.3.2    Immune evasion for human herpesviruses 
In herpes simplex virus 1 (HSV-1), viral proteins ICP34.5 and ICP0 may inhibit type I 
IFN induction by targeting cellular TBK1 and IRF3, respectively. Its ICP27 protein 
effects on IFN-α dependent signal pathway by inhibit STAT1 phosphorylation. The 
herpes Us11 protein interferes with the host defence system by blocking the antiviral 
protein OAS (Vandevenne, 2010). The Human cytomegalovirus (HCMV) evades the 
immune system by disrupting the IFN-β expression or the IFN-α signal transduction 
pathway. Its viral proteins pp65 and IE86 act as IFN-β antagnists by 
dephosphorylating IRF-3 and reducing NF- κB activation (Abate, 2004; Sanchez, 
2002). The viral proteins of Epstein-barr virus (EBV) are also found to inhibit both 
IRF-7 and IRF-3 to prevent target gene expression or binding with responsive 
promoters (Bentz, 2010). 
 
1.3.3.3    Arenaviruses 
The nucleoprotein of prototypic arenavirus Lmphocytic Choriomeningitis Virus was 
the first viral protein in the Arenaviridae family found to inhibit the type I IFN 
expression by an early block in IRF-3 activation pathway (Martinez-Sobrado, 2006). 
The experiment result shows LCMV NP blocks the activation and nuclear 
translocation of Sendai virus induced transcription factor IRF-3 to interefere with 
IFN-β promoter expression rather than directly disrupt IFN singnalling. But the 
limited expression of IFN-β will later cause the low level of antiviral proteins ISGs 
expression. The NPs from both Old World and New Wold arenavirus except Tacaribe 
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virus (TCRV) are all found to have suppression on type I IFN-β by inhibiting IRF-3. 
The NPs tested for the inhibition function are from old world arenaviruses LASV and 
LCMV, and new wold arenaviruses Junin virus (JUNV), Whitewater Arroyo virus 
(WWAV), Pichinde virus (PICV), Machupo virus (MACV), TCRV, Latino virus 
(LATV) and plus NS1 from influenza virus (Martinez-Sobrado, 2007). But so far, 
there is no structural evidence of any NPs from Arenaviridae family to support this 
theory. Structure of NP from Lassa virus then becomes the first discovery of both IFN 
immune suppression and cap snatching mechanism in Arenavirus. 
 
1.3.4    Structural bases for viral immune suppressions 
Many viruses evade from the host immune system by antagonizing antiviral signalling 
pathways. Both Ebola virus (EBOV) and Influenza A virus are found to bind dsRNA, 
this binding will consequently antagonize the host PAMP sensors to recognize the 
viral intruder and suppress the innate immune response.  
 
1.3.4.1    Ebola virus VP35 
Ebola virus is a nonsegmented, enveloped, negative-strand RNA virus that causes 
severe hemorrhagic fever. VP35 is one of the seven proteins of Ebola viruses, whose 
C-terminal interferon inhibitory domain binds dsRNA to prevent host receptors RIG-I 
and MDA-5 to recognize the pathogen intrusion. VP 35 is also a multifunctional 
protein in mediating viral replication (Cárdenas et al., 2006) and nulceocapsid 
formation, blocking interferon regulatory factor 3 (IRF-3) phosphorylation and 
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inhibiting RNA dependent protein kinase R (PKR) activation (Schumann, 2009). The 
complex structure of viral protein VP35 and dsRNA that forms a symmetric dimer 
shows two distinct ways of molecule binding: one monomer (B) binds dsRNA 
backbone and caps the blunt terminus of the dsRNA, where the other monomer (A) is 
engaged in dimerization and binding only the phosphate backbone of dsRNA 
(Kimberlin, 2010; Leung, 2010) (Fig. 1.13).   
 
 
Figure 1.13 Complex of dsRNA and Ebola virus VP35. a, the complex of dsRNA and two 
dimers of VP35 with four molecules A, B, C, D; b, the picture shows a dimer VP35 with 
molecules A and B binds an 8-bp dsRNA oligomer. The pink monomer binds the phosphate 
backbone of the dsRNA; the green monomer caps the blunt end of dsRNA (PDB code: 3L26). 
In molecule B, residues R305, K309, K319 and K339 are involved in dsRNA binding, 
residues R312 and R322 bind directly to the phospohdiester bond of dsRNA. In 
molecule A, residues R312, R322 and K309 do not contact with dsRNA, these 
residues instead form the dimerization interface between the two proteins. Another 
unique finding in this complex structure is that the central basic patch also 
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accommodates the 5’ end cap of the dsRNA by several conserved hydrophobic 
residues (Fig. 1.14).  
 
 
Figure 1.14 The residues of VP35 that are involved in phosphodiester bond binding and 
dsRNA 5’ terminal capping. a, residues R305, K309, R312, R322, K319 and K339 are key 
for binding the backbones of the dsRNA oligomer; b, residues Q274 and I340 are critical for 
binding 5’ base of dsRNA (PDB code: 3L26). 
Vertebrates have developed various receptors to recognize viral intrusion, retinoic 
acid inducible gene I (RIG-I) is one of the innate immune patterns recognition 
receptors that induce type I interferon expression. RIG-I consists of a DECH helicase 
and C-terminal domain that bind dsRNA and N-terminal domain that has two caspase 
activation and recruitment domains (CARDs). Once dsRNA and ATP bind to 
C-terminal domain (CTD) and helicase domain, the structural conformation of RIG-I 
is altered to release CARDs on N-terminal domain for downstream signalling. The 
recently published complex structures of RIG-I and blunt end 5’ppp dsRNA reveal 
that C-terminal domain of RIG-I caps the terminal base of dsRNA, whereas the 
helicase and repressor domain binds the phosphate backbone of dsRNA (Wang, 2010; 
Kowalinski, 2011) (Fig. 1.15). RIG-I is a dsRNA dependent ATPase, lacking the 
CTD significantly reducing its ATPase activity (Cui, 2008). The C-terminal domain 
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of RIG-I caps the terminal base of blunt end 5’ppp dsRNA, the electrostatics map 
shows the capping site that consists of His847, Lys849, Lys861, Lys858 and Phe853 
are positively charged. The helicase domain interact mainly with 3’ strand, whereas 
the CTD stacks the 5’ end of dsRNA.   
Figure 1.15 Structures of RIG-I in complex with blunt end 5’ppp dsRNA. a, complex 
structure of RIG-I CTD and 14mer blunt end 5’OH dsRNA (PDB code: 4A2X); b, 
electrostatics potential map of RIG-I CTD, the capping region is marked with red dash line, 
positively charged surface is colored in blue and negatively charged surface is colored in red; 
c, the complex of RIG-I helicase domain binding the backbone of 19mer dsRNA (PDB code: 
4A36). 
Combining with the in vitro and in vivo functional studies, EBOV VP35 inhibits 
IFN-β promoter activation by shielding the 5’ base of the blunt end dsRNA and 
binding the backbone of dsRNA in a similar way as RIG-I. Viral protein VP35 binds 
with dsRNA preventing the activation of RIG-I, which contributes to the evasion of 
host innate immune response of Ebola virus.  
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1.3.4.2    NS1 protein of Influenza A virus 
The non-structural 1 (NS1) protein in Influenza A virus has been reported to have 
multiple functions in both innate immune response and adaptive immune response. 
NS1 has two functional domains that are N terminal RNA-binding domain (RBD) and 
C terminal effector domain (ED). NS1 regulates the posttranscriptional steps by 
inhibiting host mRNA nuclear export, pre-mRNA splicing and activation of dsRNA 
activated protein kinase (PKR). The binding between NS1 RBD and dsRNA blocks 
the activation of PKR that is responsible for phosphorylation of the α subunit of the 
eukaryotic translation initiation factor 2 (elF2α). The virus consequently is shielded 
from the antiviral response by decreasing viral and cellular protein synthesis (Lu, 
1995). The structure of NS1 RBD-dsRNA complex shows the dimeric six helical fold 
NS1 RBD recognizes the major groove of dsRNA with the special Arg38-Arg38 and 
Arg35-Arg46 pairs (Fig. 1.16). 
Figure 1.16 The complex of dimeric NS1 RNA-binding domain and dsRNA. a, the 
dimeric NS1 with monomer 1 colored in yellow and monomer 2 colored in pink; b, residues 
Arg 35, Arg38 and Arg46 that are crucial for protein and dsRNA binding are colored in red 
(PDB code: 2ZKO). 
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The residues on the interaction surface (Arg35, Arg38, Ser42 or Thr49) of NS1 RBD 
distinguish dsRNA and dsDNA by recognizing the sugar phosphate backbone and 
2’-OH groups on the RNA strand either directly or via water bridges. The Isothermal 
Titration Calorimetry (ITC) assay shows that the R35AR46A double mutant and 
R38A mutant lose dsRNA binding function. These residues may also be critical for 
the formation of NS1 RBD dimerization (Cheng, 2009). Unlike VP35 and RIG-I, NS1 
shields viral RNA only by binding the phosphate backbone, which suggests a 
different way for influenza A virus evading from host innate immune system. 
 
1.4    Objective of this thesis 
Arenaviral nucleoprotein encapsidates with viral genomic RNA forming 
ribonucleoprotein complex, playing essential roles in viral RNA replication, 
transcription and immune suppression. However, little is known about the molecular 
mechanism. The objective of this thesis is to elucidate the molecular mechanism by 
determining LASV NP protein structure and carrying out biochemical and cellular 
studies. 
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Chapter 2:   Lassa virus NP protein over-expression         
            and purification 
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To solve the structure of LASV NP, the NP protein was prepared. In this chapter, we 
are going to discuss how to make the expression construct by molecular cloning, and 
how to express, purify and identify LASV NP protein. 
 
2.1    Preparation of Lassa NP expression construct 
The entire NP gene of Lassa fever virus (Josiah strain) that is subcloned into pLOU3 
vector (see Appendix I.2), which is a derivative plasmid from pMAL-C2X, containing 
a 6His-tag at the N-terminus of MBP and the Tev proteinase cleavage site between the 
MBP and target protein. The plasmid pCAGGS containing the LASV NP gene was 
provided by our collaborator Dr. Yuying Liang from Emory University, USA. 
 
2.1.1    The NP gene was obtained from the original plasmid 
The original plasmid pCAGGS that contains the NP gene was digested by restriction 
endonucleases EcoRI and XhoI (restriction enzymes from Promega/New England 
Biolabs). Briefly, the NP gene is cut from the plasmid in 60 µl digestion solution 
containing 50µl plasmid, 6µl Buffer H, 1µl EcoRI, 1µl XhoI, 1µl BSA and 1µl H2O. 
The digestion was carried out at 37 °C for 1.5 hours and the NP gene was separated 
and purified using 1% agarose gel electrophoresis in TAE buffer. The pLOU3 plasmid 
was prepared using the same way as the NP gene by EcoRI and SalI endonucleases 
except the plasmid had an additional treatment with 1 µl Shrimp phosphatase at 37 °C 
for 30 min, which can reduce the plasmid self-ligation. The DNAs in the agarose gel 
were stained with ethidium bromide (EB) and visualized using a UV transilluminator 
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(UVP BioDoc-It system).      
 
2.1.2    Gel extraction 
Both the NP gene and the pLOU3 plasmid treated with the enzymes were isolated 
from the 1% agarose gel using the QIAquick Gel Extraction Kit (QIAGEN) according 
to the manufacturer’s instructions. The gel slices containing proper DNA fragment 
were mixed with 3 volumes of Buffer QG and the mixture was incubated at 50°C till 
the gel was completely dissolved. Afterwards, 1 volume (equal to the weight of the 
gel) of isopropanol was added to the mixture and the sample was applied into the 
QIAquick Spin Column. After 1 minute centrifugation, the DNA was separated from 
the flow-through contaminants bound to the column. The column was washed once 
with 0.5ml of Buffer QG to remove remained agarose and twice with 0.8ml of buffer 
PE to remove contaminants. Finally the DNA was eluted using 50µl sterilized ddH2O. 
 
2.1.3    Ligation 
The NP gene fragment was inserted into the pLOU3 plasmid by T4 DNA ligase 
(Promega) and the reaction was carried out in 20 µl solution containing 3µl NP 
fragment, 5µl pLOU3, 1µl T4 ligase, 2µl T4 ligase buffer (×10) and 9 µl H2O at 16°C 
overnight. 
 
2.1.4    Preparation of competent cells 
DH5α/Tam1 E.coli cells were incubated from 1ml overnight culture in 100ml LB 
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(10g/l Bactotryptone, 10g/l NaCl, 5mM NaOH, 5g/l yeast extract) for 2 hours at 37°C 
in incubator (New Brunswick Scientific). The cultures then were chilled on ice for 30 
mins before transfer into two prechilled 50ml falcon tubes. The cultures were pelleted 
at 2800 rpm for 5 mins at 4°C, the supernatant was discarded and the tubes were put 
up side down to drain away the water. The pellets were resuspended in 12.5ml 
100mM CaCl2, 2.5ml 40mM MgSO4 and prechilled autoclaved glycerol was added to 
10% final concentration (v/v). The cells were centrifuged at 2800 rpm for 5 mins at 
4°C. The pellets were then resuspended in 2ml of ice cold 0.1M CaCl2. The 
component cells were aliquoted into 0.2 to 0.5ml and flash frozen cells in liquid 
nitrogen and stored in ultra low temperature freezer (New Brunswick Scientific) at 
-80°C. 
 
2.1.5    Transformation 
The ligation products were transformed into E.coli strain DH5α. 50µl competent cells 
were thawed on ice, and 5µl of ligated plasmids were added into the competent cells. 
The mixture was incubated for 30 minutes on ice and heat shocked at 42°C for 45 
seconds. Then cells were incubated for 2 minutes on ice, and 100µl LB medium was 
added and cells were incubated at 37°C for 1 hour at 200rpm. The cells were spread 
on an agar plate containing 50 ug/ml Ampicillin (Melford laboratories) and grown 
overnight at 37 °C. 
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2.1.6    Evaluation of NP expression plasmid  
In order to check whether the correct NP gene was inserted into the pLOU3 plasmid, 
two single clones were picked from the transformation plate, cultured separately in 
10ml LB medium in present of 100 ug/ml Ampicillin overnight at 37 °C. The 
plasmids were purified from the overnight culture using QIAprep miniprep Kit 
according to the manufacture’s instruction. Briefly, the 10 ml of E.coli overnight 
culture was transferred into a 50 ml test tube and centrifuged at 4,000 rpm for 10 
minutes at room temperature to harvest the cells. The cell pellet was resuspended in 
200µl Buffer P1 and 250µl Buffer P2 was added to lysize the cells. After gently 
mixing, 350µl Buffer N3 was added for neutralization. The mixture was then spun 
down at 13,000rpm for 10 minutes. The supernatant was loaded into a QIAprep Spin 
Column. After one-minute centrifugation, the DNA was bound to the column. The 
column was then washed twice with 0.8 ml of buffer PE to remove contaminants and 
finally the plasmids were eluted into 50µl sterilized ddH2O. 10 ul of the pLOU3-NP 
plasmids were digested with EcoRI and Hind III to cut the NP fragments from the 
plasmids and then the size of both the NP fragments were checked on a 1% agarose 
gel as describing above. The agarose gel electrophoresis showed that there is a band 
for NP gene corresponding to the right size around 1.7 Kb. The NP gene fragment is 
shown in figure3 as the lower band in the electrophoresis gel (Fig. 2.1). This result 
indicates that the NP gene was successfully inserted in the expression plasmid.  
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Figure 2.1 The electrophoresis gel of digested pLOU3-NP plasmid. Lane 1 is the 250 bp 
DNA ladder; lane 2 and lane 3 are the digested plasmids from two clones. The upper bands of 
the digested plasmids are the vector pLOU3, whereas the lower bands are the target NP gene 
fragments.    
 
2.2    Protein expression 
Once the correct plasmids were confirmed, the plasmids were transformed into 
expression strain Rosetta cells for protein expression trials as described above. 
Although other expression constructs like pLOU2 were also tried in E.coli expression 
system, only NP-pLOU3 expressed certain amount of the target NP protein. The 
single colony from Rosetta transformation plate was then picked and inoculated into 
500 ml LB medium in present of 50 μg/ml Ampcilin and 34 μg/ml chloramphenicol 
(Duchefa Biochemic), and cultured overnight at 37 °C and 200 rpm. The overnight 
culture was inoculated into 10 liters of the LB medium containing 50 μg/ml Ampcillin 
and 34μg/ml chloramphenicol. The cell cultures were incubated at 37°C and 200 rpm 
in an incubator. The NP protein was induced by 
isopropyl-beta-d-thiogalactopyranoside (IPTG) to a final concentration of 0.03mM 
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when the OD600 of the cell culture reached to 0.6. The NP protein was induced 
overnight at 20°C. 
 
2.3    Protein purification 
2.3.1    Methods of purification 
The cells were harvested by centrifugation at 8,000g for 10 min at 4 °C. The cell 
pellet collected from 10L culture was resuspended in 100 ml of amylose binding 
buffer (10% glycerol, 20mM Tris pH7.5, 0.2M NaCl and 1mM EDTA) with 2 
protease inhibitor tablets (Roche), 1 uM DNase I (Sigma) and 1 mM 
Phenylmethylsulfonyl fluoride (PMSF) (Sigma). The cells were disrupted by a cell 
disruptor (Constant system Ltd) and the broken cell mixtures were centrifuged at 
20,000 rpm for 30 min to remove the cell debris. The supernatant was applied into an 
amylose column and the column was washed using 10 column volumes of amylose 
binding buffer. The fusion protein was eluted with amylose elution buffer (10% 
glycerol, 20mM Tris pH7.5, 0.2 M NaCl, 1mM EDTA and 10 mM Maltose). The 
protein buffer was changed to Tev cleavage buffer  (1/50 PBS, 50 mM Tris-HCl, 0.5 
mM EDTA, 1 mM DTT, 0.3 M NaCl and 10% glycerol) using a desalting column 
(Hiprep 26/10, GE healthcare). Fractions containing HisMBP-NP was pooled and the 
fusion protein was cleaved with 1 ml His-taggedTEV protease at room temperature 
overnight. The cleaved sample was applied to the amylose resin again to remove the 
MBP. The flow-through sample was concentrated to 5 ml and the NP protein was 
purified by a gel filtration column (Hiload
TM
 16/60 Superdex 200, GE healthcare) that 
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was equilibrated by the gel filtration buffer (20mM Tris pH 7.5, 0.3M NaCl and 10% 
glycerol).  
 
The fractions containing purified NP protein was pooled and concentrated to 7 mg/ml 
and frozen at -80 °C. The protein’s identity and integrity were checked by 
Electrospray ionization mass spectrometry (ESI-MS) and SDS-PAGE protein gel. The 
SDS-PAGEs were carried out using pre-cast NuPAGE 4-12% Bis-Tris gels and 
Powerease 500 according to the manufacturer’s manual, with the protein molecular 
standards of Mark12 unstained standard (Invitrogen). The concentration of purified 
protein was determined using Bradford solution (Sigma Aldrich) and BSA as standard 
protein.  
 
2.3.2    Evaluation of NP protein purification  
The NP protein was successfully expressed as a MBP fusion protein, and the fusion 
protein was purified and finally the MBP fusion protein was cleaved off by Tev 
proteinase. As shown in figure 2.2, although there is still certain amount of NP protein 
in the flow-through, the eluted NP protein is enough for the next purification step, 
which shows that the expression of the NP protein was very successful. After the 
cleavage by Tev proteinase and going through the amylose column, almost all the 
MPB and uncleaved fusion protein were removed. After gel filtration, NP protein was 
purified (Fig. 2.3 & 2.4). The protein was finally concentrated to 7 mg/ml and the 
volume is around 1.5ml, which means a total amount of 10.5 mg NP protein was 
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obtained from the 10-liter culture.  
 
  
 
 
 
 
 
 
 
 
 
Figure 2.2 The LASV NP was purified by amylose beads. The expression level of NP and 
the first purification step after tev proteinase cleavage are shown by SDS-PAGE gel. Lane 1: 
Protein Marker 12; lane 2 flow-through proteins from amylose resin; lane 3 NP elution from 
amylose resin; lane 4 proteins after tev proteinase cleavage. 
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Figure 2.3 The LASV NP protein purification by gel filtration column. The gel filtration 
chromatography was carried out using a superdex 200 column, the first peak is NP protein 
and the second peak is MBP. 
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Figure 2.4 SDS-PAGE protein gel for samples from gel filtration. Lane 1 Protein Marker 
12; lanes 2 to 11 are NP protein from peak 1; lanes 12 to 16 show the MBP and tev proteinase 
from peak 2; lanes 7 to 11 fractions were pooled and concentrated.  
 
2.3.3    Identification of NP 
To confirm the identity of the target NP protein, the band on SDS-PAGE after gel 
filtration was cut and sent for the electrospray ionization mass spectrometry (ESI-MS). 
The trypsin digestion with mass spectroscopy confirmed that the purified protein was 
the NP of Lassa fever virus. To determine the whole protein molecular weight by 
mass spectrum, the purified protein was submitted for analysis. The whole mass of 
native NP was determined to be 64,240 Da (as shown in Fig. 2.5), which matches 
calculation from the amino acid sequence. 
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Figure 2.5 The Electrospray ionization mass spectrometry (ESI-MS) result of native NP 
protein. 
 
2.3.4    Expression, purification and crystallization of Selenomethionine  
(SeMet) labeled protein 
As there is no any similar structure available in the PDB database for structure 
determination using molecular replacement. We therefore decided to determine the 
structure by Selenomethionine (SeMet) labeled crystals using multi wavelength 
anomalous diffraction (MDA). The SeMet labeled protein was set to express in E.coli 
system, unfortunately the level of expression is very poor. The NP protein was 
cultured in SeMet medium which was prepared as follows (per litre): 1g NH4Cl, 3g 
KH2PO4, 6g Na2HPO4·7H2O, 20g glucose 0.3g MgSO4, 1g NaCl, 35ml glycerol, and 
0.5g of each of the 19 common amino acid (excluding Met). The final pH was 
adjusted to around 7.4. The antibiotic Ampicillin was added to 50ug/ml, 
chloramphenicol was added to final concentration at 34ug/ml. When OD600 reaches 
0.7, amino acids lysine, phenylanaline, and threonine were added at 100 mg/liter; 
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amino acids isoleucine, leucine and valine were added at 50 mg/liter; 0.02g thiamine 
and biotin were added to the culture. 50mg SeMet was added after 10 mimutes, the 
temperature was adjusted to 20°C when 0.03mM IPTG was added after another 10 
minutes. The purification steps are the same as native protein. However, we were 
unable to crystallize the labeled protein. The phase problem was then solved by heavy 
atom samarium soaking during structure determination (see section 3.1.3). 
 
2.3.5    Different multimerization of LASV NP 
According to the slightly shift curve on the first peak in the gel filtration map (Fig. 
2.3), the purified nucleoprotein was assumed to have two forms of oligomers. In order 
to check whether there are two forms of the NP protein, the purified NP protein was 
applied into a Superdex 200 10/300 (GE Healthcare Life Sciences) column using a 
buffer containing 20mM Tris pH 7.5, 0.3M NaCl and 10% glycerol. To calibrate the 
column, protein standards (Sigma) including five proteins thyroglobulin, y-globulin, 
ovalbumin, myoglobulin and vitb12 were run with the same buffer. The gel filtration 
result is shown in figure 2.6. According to the elution volumes of the protein 
standards, a standard curve was obtained with an equation y= -0.5764x + 19.336 (Fig. 
2.7). 
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Figure 2.6 The gel filtration of protein standard from Superdex 200 10/300 column. The 
five protein standards are peak 1: thyroglobulin, peak 2: y-globulin, peak 3: ovalbumin, peak 
4: myoglobulin, peak 5: vitb12. 
 
 
Figure 2.7 The equation for calculating NP molecular weight based on the elution 
volume (X) and the In(Molecular Weight) (Y) of the five standard protein.  
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Figure 2.8 Gel filtration of NP protein by a Superdex 200 column. There are two main 
peaks, indicating NP protein has two forms, which are hexamer (peak 1) and trimer (peak 2). 
 
Table 2.1 The statics table of the molecular weight of oligomer NP (protein x and 
protein y) that is calculated based on five standard protein thyroglobulin, y-globulin, 
ovalbumin, myoglobulin and vitb12. 
standard Peak MW ln(MW) Ve 
calculated 
MW in kDa error % 
thyroglobulin b 670000 13.4 9.8 1027658 1028 53 
y-globulin c 158000 12.0 12.9 196511 197 24 
ovalbumin d 44000 10.7 15.5 50520 51 15 
myoglobulin e 17000 9.7 17.2 20267 20 19 
vitb12 d 1350 7.2 20.4 3780 4 180 
                
unknown               
protein x 1     10.9 466606 467   
protein y 2     12.7 165334 165   
 
100 ul of the purified NP protein was then loaded into the column, and the gel 
filtration was carried out according to the manufacture’s instruction (Fig. 2.8). There 
are two main peaks appeared. The elution volume for peak 1 is 10.9ml, which 
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indicates the molecular weight of the oligomer NP is around 467kDa. The mass of 
native NP protein is around 64kDa, which means there are almost 6 monomers in this 
oligomer (Table 2.1). Since the accuracy of this equation shifts with the elution 
volume, and based on the observation of other NP protein, this oligomer NP is 
hexamer. The elution volume of the second peak is 12.7 ml, indicating the molecular 
weight is around 165kD, which means there are 3 monomers in this oligomer, 
indicating NP oligomer is trimer. A recent published paper (Brunotte, 2011) also 
confirmed the existence of the symmetric trimer of Lassa virus nucleoprotein (AV 
strain) by presenting small-angle X-ray scattering (SAXS) and electron microscopy 
(EM) result.  
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   Chapter3: Structure of Lassa nucleoprotein 
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In this chapter, we determine the molecular structure of LASV NP protein. Each of 
the functional domains is described in detail on the basis of corresponding amino 
acids. Both the exoribonuclease activity site and the potential cap binding site are 
revealed from this structure. The oligomerization and the interface between each 
monomer are also present in the following chapter. 
  
3.1    Native NP crystal structure 
3.1.1    Crystallization of native Lassa NP 
Crystallization conditions for LASV NP were screened on 2 well MRC plates with the 
sitting drop vapor diffusion method using Cartesian Dispensing systems. The drops 
were built with 0.15 ul of the protein and 0.15 ul of the mother liquid using two 
different protein concentrations (7 mg/ml and 3.5 mg/ml), with 100 ul of mother 
liquid in each reservior. The Classic, JCSG+, Nextal, PEGs, and PEGs II (Hampton, 
Jena, Qiagen) kits were used in the initial screenings. The initial crystals were formed 
in 0.2 M LiCl, 20% PEG3350 at 20°C for a week. After optimization, hexagonal 
prism crystals were grown in 0.2-0.3 M LiCl and 12-16% PEG3350 at 20 °C for 5 
days. The optimization buffer conditions are list below (Table 3.1).  
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  Table 3.1 Optimization buffer conditions for crystallizing NP protein. 
         
PEG3350 
(v/m, %)   
           LiCl 
(M)   
    
        
0.15 0.2 0.25 
       
0.3 
    240ul   PEG 240ul   PEG 240ul   PEG 240ul   PEG 
                      
12   75ul     LiCl 100ul   LiCl 125ul   LiCl 150ul   LiCl 
    685ul   H2O 660ul   H2O 635ul   H2O 610ul   H2O 
    280ul   PEG 280ul   PEG 280ul   PEG 280ul   PEG 
                      
14   75ul     LiCl 100ul   LiCl 125ul   LiCl 150ul   LiCl 
    645ul   H2O 620ul   H2O 595ul   H2O 570ul   H2O 
    320ul   PEG 320ul   PEG 320ul   PEG 320ul   PEG 
                      
16   75ul     LiCl 100ul   LiCl 125ul   LiCl 150ul   LiCl 
    605ul   H2O 580ul   H2O 555ul   H2O 530ul   H2O 
    360ul   PEG 360ul   PEG 360ul   PEG 360ul   PEG 
                
18   75ul     LiCl 100ul   LiCl 125ul   LiCl 150ul   LiCl 
    565ul   H2O 540ul   H2O 515ul   H2O 490ul   H2O 
    400ul   PEG 400ul   PEG 400ul   PEG 400ul   PEG 
                
20   75ul     LiCl 100ul   LiCl 125ul   LiCl 150ul   LiCl 
    525ul   H2O 500ul   H2O 475ul   H2O 450ul   H2O 
    440ul   PEG 440ul   PEG 440ul   PEG 440ul   PEG 
                      
22   75ul     LiCl 100ul   LiCl 125ul   LiCl 150ul   LiCl 
    485ul   H2O 485ul   H2O 485ul   H2O 485ul   H2O 
    480ul   PEG 480ul   PEG 480ul   PEG 480ul   PEG 
                      
24   75ul     LiCl 100ul   LiCl 125ul   LiCl 150ul   LiCl 
    445ul   H2O 420ul   H2O 395ul   H2O 370ul   H2O 
 
The NP protein crystals grew with dimension of 0.2 × 0.2 × 0.6 mm, which are 
suitable for X-ray diffraction. To confirm the crystal is from the whole NP protein, a 
crystal was picked up and washed three times in a cryoprotectant, and dissolved in 
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SDS-loading buffer for SDS-PAGE. The result showed there was a single band 
corresponding to the whole NP protein’s molecular weight (Fig. 3.1)        
 
Figure 3.1 The crystals of native Lassa NP protein. a, Photograph of the NP crystals from 
Lassa fever virus; b, the SDS-PAGE gel of dissolved native NP crystal, indicating the crystals 
were from the whole NP protein. 
 
3.1.2    In house X-ray data collection 
All the crystals were cryo-protected with a cryoprotectant containing 15% to 20% 
glycerol, 0.2 M LiCl2, 16% PEG3350. The crystal which is primitive hexagon were 
first tested using in house Rigaku MicroMax-007 HFM fine focus X-ray generator 
and CCD detector Saturn 944+ with Actor robot. One of the crystals was selected and 
the data were collected at oscillation angel 0.1° and 100 second exposure per frame 
with 60 mm of distance from the crystal to detector, using the Cu radiation with the 
wavelength of 1.5418Å. Total 1000 frames were recordered. The in house processed 
data indicates that the crystal belongs to space group P321. The unit cell parameters 
a b 
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are a = b = 176.35 Å, c = 56.40 Å, α = β = 90° and γ = 120°. The data processed to 
resolution 2.36 Å and the detail statistics are list in table 3.2. 
Table 3.2 In house data collection statistics of the native NP protein crystal. 
Data collection Values 
Wavelength (Å) 1.5418 
Resolution (Å)                                        
50-2.36 (2.40-2.36) 
Space group 
P321 
Cell dimension (Å, °)                              
a = b = 176.35 c = 56.40 
 
α = β = 90  γ = 120 
No. unique reflections 
41405 (1998) 
Completeness 
99.7 (97.1) 
Redundancy 5.4 (3.9) 
I/σ(I) 
27.6 (7.2) 
 
Rmerge
*
 
0.057 (0.166) 
* Rmerge=ΣhklΣi|Ii(hkl)-(I(hkl))|/ ΣhklΣiIi(hkl), h, k, l-indices of independent reflections 
with the average intensity <I>, Ii-intensities of independent reflections. 
 
The final data were collected at IO2 and IO3 of Diamond light sources UK with the 
crystals protected by cryoprotectant that contain 15% to 20% glycerol in the 
crystallization conditions. The high resolution data sets of native NP were collected to 
a resolution of 1.8 Angstrom (Table 3.3). 
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Table 3.3 Data collection statistics of native crystal at synchrotron: 
Data collection Values 
Wavelength (Å) 0.979 
Resolution (Å)                                        
47.63-1.80 (1.81-1.795) 
Space group 
P321 
Cell dimension (Å, °)                              
a = b = 177.16. c = 56.49 
 
α = β = 90  γ = 120 
No. unique reflections 
184629 (5543) 
Completeness 
99.7 (99.9) 
Redundancy 5.6 (5.5) 
I/σ(I) 
16.4 (4.2) 
 
Rmerge 
0.073 (0.393) 
 
3.1.3    Phase determination 
As no similar structures exist in PDB database for structure determination using 
molecular replacement, and we could not obtain selenomethionine labelled NP 
crystals, we have tried to soak different heavy atoms to the native crystals in order to 
find the phase for the LASV NP structure determination using in house x-ray machine. 
Only samarium soaking allowed us to collect good data to show good anomalous 
signals. We therefore decided to collect MAD datasets for the structure determination 
at Diamond I03 beamstation. The MAD data sets were collected at a wavelength of 
1.8Å for peak data, 1.8Å for inflection data and 1.45Å for remote data from a single 
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crystal (Table 3.4).  
Table 3.4 The MAD data collection for NP crystal at synchrotron: 
Data collection 
Multiwavelength experiment 
peak inflection remote 
Wavelength Å 1.83 1.84 1.45 
Space group P3 P3 P3 
Resolution(highest shell) Å 
57.86-2.5 57.94-2.5 58.00-2.5 
(2.53-2.50)     
  (2.53-2.50) (2.53-2.50) 
Cell constants (Å) 
α=β=90°, γ=120° 
a=b=176.75, c=56.35 a=b=177.01, c=56.45 a=b=177.20, c=56.54 
Unique reflections 68131(2042) 68424(2029) 68691(2057) 
Average redundancy 5.5(5.4) 5.5(5.4) 5.6(5.5) 
I/σ 
15.3 13.6 15.5 
(4) (2.6) (3.3) 
Completeness 
100 (100) 100 (100) 100 (100) 
(%) 
Anomonous 
97.1 
(92.6) 
97.1 99.1 
Completeness (93.2) (97.4) 
(%)     
(High resolution shell) 0.062 0.066 0.06 
Rmerge  (0.342) (0.541) (0.433) 
 
The original data were indexed and scaled by imosflm and ccp4i, respectively (Fig. 
3.2 & 3.3) 
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Figure 3.2 X-ray diffraction pattern of optimized crystal of native NP protein. The 
yellow spots are partially recorded reflection and the red spots are spatially overlapped 
reflection that will not be integrated. 
               
 
 
Figure 3.3 Indexing of native NP protein crystal data by imosflm. The p3 space group was 
selected after indexing. 
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After indexing, space group P3 was suggested during processing data from native NP 
protein by imosflm. The final data sets were collect from Diamond light sources UK, 
the data sets processed for multiwavelength anomalous dispersion (MAD) method 
with samarium derivative native NP are listed above (Table 3.4). The crystals were 
soaked in 100 mM samarium acetate in 0.2 M LiCl and 16% PEG3350 overnight and 
back soaked into 15% glycerol, 0.2M LiCl and 16% PEG3350 for 5 min. The crystals 
were frozen in liquid nitrogen and the data were collected in IO2 station of Diamond. 
The crystals were scanned by fluorescence scanner to determine the peak, inflection 
and remote wavelengths to collect complete MAD datasets. More than twenty crystals 
were screened and one of the best crystals was chosen to collect individual peak 
wavelength, inflection wavelength and remote wavelength datasets. The three datasets 
were indexed and integrated by imosflm and scaled by ccp4i SCALA separately. 
 
3.1.4    Model building and refinement of Lassa NP crystal structure 
Although the original structure was determined by SOLVE and RESOLVE with the 
space group of P321, the real space group P3 with three subunits in an asymmetric 
unit that was found during refinement will be used in this thesis. By using the multiple 
wavelength anomalous diffraction (MAD) data sets, the initial phases were obtained 
with samarium derivative data were processed by Phenix Autosolve, the initial 
electron density map was then assigned to build the model by Buccaneer and Coot.  
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Figure 3.4 The 2Fo-Fc electron density map that contoured at 1.8σ is colored in 
blue. The crystal structural model that references to the amino acid sequence of 
LASV NP is built manually. 
 
The high-resolution native NP structure was then determined using molecular 
replacement and the initial NP model built by buccaneer. The structure was built by 
Coot (Fig. 3.4), and the structure was refined and de-twinned by using REFMAC5. 
The water molecules were added into the structure by ARP/wARP. To improve the 
initial phases, the trial strucutures were then interactively processed between real 
space and reciprocal space until the Rfactor and Rfree reached 0.1781 and 0.2014, 
respectively.  
 
During structure refinement, the crystal was found heavily twined with a twining 
fraction of 0.43, as we could not drop the Rfree and Rfactor from 0.37 and 0.32 for 
the 1.8 Å data, the structure then refined and de-twinned by using REFMAC5. The 
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final model was obtained with Rfactor and Rfree reach to 0.178 and 0.201, respectively 
(Table 3.5). At last, the structure models were evaluated by MolProbity.   
Table 3.5 Refinement statistics of native NP crystal structure. 
Refinement Native NP 
Rfactor
a 0.178 
Rfree
b 0.201 
Rmsd bonds   
0.04/2.62 
(Å)/angels (°) 
Residues in 
96.83 Ramachandran 
core (%) 
PDB ID 3MWP 
a Rfactor = Σ ||Fobs – Fcalc|| / Σ|Fobs|, Fobs is the observed structure factors, wherea Fcalc is 
the calculation structure factors. 
b Rfree measures the degree to which the model predicts the diffraction data for the test 
set. 
  
The final model has an excellent geometry with 97.15% of the total residues in 
preferred regions, 2.58% of the total residues in allowed regions and only 0.20% of 
total residues (1 residue) in outliers (Fig. 3.5). The electron densities for residues 1-6, 
147-157, 339-363, 518-521, 562-569 were not well defined, indicating the residues in 
these regions are disorded. The final protomer model contains 514 residues from the 
total 569 residues. The model of LASV native NP protein was deposited into the PDB 
with the accession code 3MWP. 
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Figure 3.5 Ramachandran plot of the Lassa NP monomer structure. Produced with 
Ramachandran Plot program by Coot. 
 
 
3.2    Overall structure of LASV NP 
Like other viral NPs (Aurélie, 2006; MacLellan, 2007), the LASV NP structure 
contains two distinct domains which are the N-terminal domain and the C-terminal 
domains. However, the two domain structures are totally different from any known 
nucleoprotein structures of other negative-stranded viruses such as Influenza virus, 
Vesicular Stomatitis virus, Rabies virus, Respirary syncytical virus and Borna virus 
(Table 3.6). The NP protomer consists of 24 α-helix and 12 β-strands, with C-terminal 
domain forming the head, N-terminal domain forming the body and residues 339-363 
disordered in between (Fig. 3.6). In the structure, we also have not found the RNA. To 
date, this is the first crystal structure of nucleoprotein in Arenaviridae family. 
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Figure 3.6 The monomer model of native NP crystal structure consists of C-terminal 
domain (residue 364 to 561) and N-terminal domain (residue 7 to 338) (PDB code: 
3MWP).  
 
Table 3.6 Structural comparison of LASV NP and other negative strand RNA     
viruses.                                     
NP DALI score* RMS 
deviation (Å) 
Number of 
aligned 
C-alpha 
atoms 
Total residues PDB code 
Influenza 
virus 
1.7 4.1 54 499 2iqh 
Vesicular 
stomatitis 
virus 
1.2 3.6 50 421 2gic 
Rabies virus 0.8 2.9 42 450 2gtt 
Borna virus 1.8 3.1 41 375 ln93 
Respirary 
syncytical 
virus 
0.8 5.6 63 391 2wj8 
٭
The scores below 2 are not significant. The analysis was performed using the DaliLite server  
http://www.ebi.ac.uk/Tools/dalilite/index.html. 
Zn
2+
 
C terminal 
domain 
N terminal 
domain 
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Amino acid sequence alignment of NPs from Arenaviridae family members, Lassa 
fever virus (LASV) (sequence access number P13699), Sabia virus (Q90038), 
Chapare virus (B2C4J1), Junin virus (P14239), Machupo (P26578), Guanarito 
(Q8AZ66), Pichinde virus (P03541), Lymphocytic choriomeningitis virus (P09992) 
and Tacaribe virus (P18140) are shown in figure 30, which shows that the NPs share 
very high similarity in amino acid sequence (almost 32% identity) (Fig. 3.7). That 
means that the LASV NP model can be served a good model for other nucleoprotein 
of arenaviruses, and the discoveries from the LASV NP can apply to other arenaviral 
nucleoprotein.  
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Figure 3.7 Sequence alignment of arenaviral NP proteins. The amino acid sequence of the 
NPs from the arenavirus family is highly conserved. LASSA, SABVB, CHAVB, JUNIN, 
MACHU, GTOVV, PIARV, LCMV and TACV represent Lassa fever virus (LASV) 
(sequence access number P13699), Sabia virus (Q90038), Chapare virus (B2C4J1), Junin 
virus (P14239), Machupo (P26578), Guanarito (Q8AZ66), Pichinde virus (P03541), 
Lymphocytic choriomeningitis virus (P09992) and Tacaribe virus (P18140), respectively. The 
secondary structures shown were based on the LASV NP structure. The conserved residues 
are shown in red. The residue D389 of TACV NP (corresponding to G392 of LASV NP) is 
indicated by ^. 
 
3.3    Structural analysis of LASV NP 
3.3.1    The structure of N-terminal domain of LASV NP 
The N-terminal domain of LASV NP (residues 7 to 338) mainly consists of α-helices 
and coils. There are 16 α-helices and 4 β-strands within this structural model. The first 
visible residue of N-terminal domain is I7 which is located on α1-helix (colored in 
blue) at the front of the model picture shown below (Fig. 3.8a), the polypeptide chain 
then goes around the model from outside to inside for the next 15α-helices and 4 
β-strands. The N-terminal domain forms a body-like structure. The bottom of the 
structure is made of helices α2, α8, α9, α10, α11 and α12, and the back made of two 
parallel helices α3, α4, helices α6, α7, and β strands β2 and β3, and the abdomen 
composed of helices α1, α5, α13, α14, α15, α16, α17 and anti-parallel β1 and β4 
 67 
strands.  
  
The N-terminal domain terminates at residues L338 that is a short loop right after β4. 
The N-terminal domain adopts a novel fold that could be the cap binding site for 
cellular mRNA within its center where the electrostatic surface potential map (Fig. 
3.14 a) shows that there is a highly positively charged cavity. But the comparison of 
LASV NP and other well-known cap bingding proteins as vaccinia methyl transferase, 
human nuclear cap binding protein, mouse eIF4E and influenza virus cap binding 
protein PB2 from Dali server indicates that there is no structural similarity (Table 
3.7). The following mutation study at binding site and functional study will be 
presented in the next chapter. 
 
 
Figure 3.8 The structural model of N-terminal domain of LASV NP, whereas b is after 
90° rotation to a along y-axis.  
 
 
 
 
 
 
 
90° 
a b 
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Table 3.7 Structural comparison of the N domain of LASV NP with other well-known 
cap-binding proteins using the DaliLite server.  
*Score below 2 is not significant. 
# The Dali server failed to provide a score due to the dissimilarity of the two structures. 
 
 
 
3.3.1.1    LASV NP structure in complex with dTTP 
3.3.1.1.1    Crystallization of native NP and dTTP 
As the N-terminal domain of the LASV NP has a highly positive charged cavity, we 
speculated that the cavity might be a cap binding site. To test this hypothesis, we tried 
to soak m
7
GpppG, triphosphorylated, dephosphorylated and monophosphorylated 
ribonucleotides. The NP complexed with dTTP was obtained by co-crystallization of 
NP protein with 50mM dTTP in 0.2M LiCl2 and 20% PEG3350 at 20°C.  
 
 
 DALI 
score* 
RMS 
deviation 
Number of 
aligned 
C-alpha 
atoms 
Total 
residues 
PDB code 
Vaccinia 
methyl 
transferase 
No
# 
  294 1av6 
Human 
nuclear cap 
binding 
protein  
0.7 4.0 57 621 1h2t 
Mouse 
elF4E 
0.8 3.9 62 181 1ej1 
Influenza 
virus cap 
binding 
protein 
PB2 
0.9 3.3 42 164 2vqz 
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3.3.1.1.2    Data collection 
The data of the NP and dTTP complex structure were collected at IO3 of Diamond 
light sources UK with the crystals protected by cryoprotectant that contain 15% to 
20% glycerol, 0.2 M LiCl2, 16% PEG3350. The space group is also P3, the unit cell 
parameters are a = b = 176.15 Å, c = 56.47 Å, α = β = 90° and γ = 120°. The data 
processed to resolution 1.98 Å and the detail statistics are list in table 3.8. 
Table 3.8 Data collection statistics of NP in complex with dTTP: 
Data collection Values 
Wavelength (Å) 0.978 
Resolution (Å)                                        
29.75-1.98 (2.09-1.98) 
Space group 
P3 
Cell dimension (Å, °)                              
a = b = 176.15  c = 56.47 
 
α = β = 90  γ = 120 
No. unique reflections 
134699 (19075) 
Completeness 
99.2 (95.8) 
Redundancy 3.8 (3.6) 
I/σ(I) 
11.9 (2.6) 
 
Rmerge 
0.074 (0.565) 
 
3.3.1.1.3    The dTTP structure determination and refinement 
The NP/dTTP compelx structure was determined by molecular replacement based on 
the native NP crystal structure. After the initial model was built, several cycles of 
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building and refinement were performed until the Rfactor and Rfree reached to 0.154 and 
0.182 (Table 3.9). The Fo-Fc maps were calculated before the ligands dTTP was added 
into the structure. 
Table 3.9 The refinement stastics of NP and dTTP complex. 
Refinement dTTP complex 
Rfactor 0.154 
Rfree 0.182 
Rmsd bonds   
0.02/1.61 
(Å)/angels (°) 
Residues in 
95.21 Ramachandran 
core (%) 
PDB ID 3MX2 
 
The structure was refined and de-twinned by using REFMAC5, and the water 
molecules were added into the structure by ARP/wARP. At last, the structure model 
was evaluated by MolProbity. The coordinate and structure factor of LASV NP with 
dTTP were deposited into the PDB with the accession code 3MX2 (Fig. 3.9). 
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Figure 3.9 The crystal structure model of NP in complex with dTTP. Both the C terminal 
domain and the N terminal domain of NP are colored in green, whereas the ligand dTTP is 
colored in magenta and orange based on the element. 
 
3.3.1.2    LASV NP structure in complex with UTP 
3.3.1.2.1    Crystallization of native NP and UTP 
UTP is an another cap analogue, which is more similar to cap structure with 2-OH 
presents in nucleotide. To check how UTP binds in the cavity, the NP complexed with 
UTP was obtained by co-crystallization of NP protein with 50mM UTP in 0.2M LiCl2 
and 20% PEG3350 at 20°C.  
C 
N 
Zn
2+
 
dTTP 
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3.3.1.2.2    Data collection 
The data of the NP and UTP complex structure were collected at IO3 of Diamond 
light sources UK with the crystals protected by cryoprotectant that contain 15% to 
20% glycerol, 0.2 M LiCl2, 16% PEG3350. The space group is also P3, the unit cell 
parameters are a = b = 177.11Å, c = 56.72Å, α = β = 90° and γ = 120°. The data 
processed to resolution 1.91 Å and the detail statistics are list in table 3.10. 
Table 3.10 Data collection statistics of native NP in complex with UTP: 
Data collection Values 
Wavelength (Å) 0.978 
Resolution (Å)                                        
88.56-1.91 (1.96-1.91) 
Space group 
P3 
Cell dimension (Å, °)                              
a = b = 177.11  c = 56.72 
 
α = β = 90  γ = 120 
No. unique reflections 
79046 (5845) 
Completeness 
99.9 (99.9) 
Redundancy 4.5 (4.2) 
I/σ(I) 
12.6 (3.3) 
 
Rmerge 
0.075 (0.482) 
 
3.3.1.2.3    The UTP complex structure determination and refinement 
The NP/UTP complex structure was determined by molecular replacement based on 
the native NP crystal structure. After the initial model was built, the refinement and 
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model building cycles were performed until the Rfactor and Rfree reached to 0.186 and 
0.225 (Table 3.11). The Fo-Fc maps were calculated before the ligands UTP was 
added into the structure. 
Table 3.11 The structure refinement statistics of NP and UTP complex. 
Refinement UTP complex 
Rfactor 0.186 
Rfree 0.225 
Rmsd bonds   
0.02/1.78 
(Å)/angels (°) 
Residues in 
94.46 Ramachandran 
core (%) 
PDB ID 3MX5 
 
The structure was refined and de-twinned by using REFMAC5, and the water 
molecules were added into the structure by ARP/wARP. At last, the structure model 
was evaluated by MolProbity. The model of LASV NP in complex with UTP was 
deposited into the PDB with the accession code 3MX5 (Fig. 3.10).   
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Figure 3.10 The crystal structure model of NP in complex with UTP. Both the C terminal 
domain and the N terminal domain of NP are colored in green, whereas the ligand UTP is 
colored in magenta and orange based on the element. 
 
3.3.2    The structure of C-terminal domain of LASV NP 
Since almost 25 residues are disordered between the N-terminal domain and 
C-terminal domain, the first residue that can be seen is alanine 364. The C-terminal 
domain (residues 364-561) of LASV NP forms the head-like structure that consists of 
one anti-parallel β sheet (β5, β6 and β7 strands) in the center which surrounded by 
helix α17, α 19, α 20, α 24 and strands β10, β11 and β12 at one side and helices α18, 
Zn
2+
 
C 
N 
UTP 
 75 
α21, α22, and α23 at the other side, and one parallel β sheet (â8 and â9). The centered β 
sheet is composed of three anti-parallel β strands forming sandwich architecture.  
The strands β5, β6 and β7 of the first β sheet are connected to each other head to tail 
by loop only, and each of them is in opposite orientation to the adjacent strand. The 
β8 and β9 strands form the second β sheet. These two β strands are parallel to each 
other with a 30ºkink separated by α21 (Fig. 3.11).  
 
Figure 3.11 The structural model of C-terminal domain of LASV NP, whereas b is 90° 
rotated to a along x-axis. Manganese ion is colored in black sphere, while zinc ion is colored 
in blue sphere. 
 
To search the similar structure of C-terminal domain in PDB, LASV NP C-terminal 
domain structure coordinate was put into Dali server 
(http://ekhidna.biocenter.helsinki.fi/dali_server), and it was very surprise that the 
C-terminal domain is very similar to several known 3’-5’ 
exonucleases/exoribonucleases, which are from the DEDDH subfamily of the DEDD 
(DnaQ) superfamily (Fig. 3.12) as below. 
 
 
 
 
90° 
a b 
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No:  Chain   Z    rmsd lali nres  %id PDB  Description 
   1:  1j54-A 10.6  2.4  126   174   13 PDB  MOLECULE: DNA POLYMERASE III, 
EPSILON CHAIN;                          
   2:  1j53-A 10.6  2.4  126   174   13 PDB  MOLECULE: DNA POLYMERASE III, 
EPSILON CHAIN;                          
   3:  2ido-A 10.3  2.4  126   172   13 PDB  MOLECULE: DNA POLYMERASE III 
EPSILON SUBUNIT;                         
   4:  2gui-A 10.2  2.4  125   176   14 PDB  MOLECULE: DNA POLYMERASE III 
EPSILON SUBUNIT;                         
   5:  2ido-C 10.2  2.4  127   175   13 PDB  MOLECULE: DNA POLYMERASE III 
EPSILON SUBUNIT;                         
   6:  1y97-B  8.6  2.9  125   211   12 PDB  MOLECULE: THREE PRIME REPAIR 
EXONUCLEASE 2;                           
   7:  2ioc-A  8.5  3.0  127   218   10 PDB  MOLECULE: THREE PRIME REPAIR 
EXONUCLEASE 1;                           
   8:  1w0h-A  8.5  2.9  127   200   15 PDB  MOLECULE: 3'-5' EXONUCLEASE 
ERI1;                                     
   9:  2ioc-B  8.4  3.0  127   220   11 PDB  MOLECULE: THREE PRIME REPAIR 
EXONUCLEASE 1;                           
  10:  2o4g-A  8.4  3.0  127   217   10 PDB  MOLECULE: THREE PRIME REPAIR 
EXONUCLEASE 1;                           
  11:  3b6p-D  8.4  3.0  127   217   10 PDB  MOLECULE: THREE PRIME REPAIR 
EXONUCLEASE 1;                           
  12:  2o4g-D  8.4  3.0  127   217   11 PDB  MOLECULE: THREE PRIME REPAIR 
EXONUCLEASE 1;                           
  13:  3b6o-D  8.4  3.0  127   217   11 PDB  MOLECULE: THREE PRIME REPAIR 
EXONUCLEASE 1;                           
  14:  2o4i-B  8.4  3.0  128   218   11 PDB  MOLECULE: 5'-                                                         
  15:  3b6o-A  8.4  3.0  127   217   11 PDB  MOLECULE: THREE PRIME REPAIR 
EXONUCLEASE 1;                           
  16:  2o4g-C  8.4  3.0  126   217   11 PDB  MOLECULE: THREE PRIME REPAIR 
EXONUCLEASE 1;                           
  17:  3b6p-A  8.4  3.0  127   217   11 PDB  MOLECULE: THREE PRIME REPAIR 
EXONUCLEASE 1;                           
  18:  2oa8-A  8.3  3.0  127   220   11 PDB  MOLECULE: THREE PRIME REPAIR 
EXONUCLEASE 1;                           
  19:  2o4i-A  8.3  3.0  127   218   11 PDB  MOLECULE: 5'-                                                         
  20:  2o4g-B  8.3  3.0  127   217   10 PDB  MOLECULE: THREE PRIME REPAIR 
EXONUCLEASE 1;                           
  21:  3b6p-C  8.3  3.0  127   217   11 PDB  MOLECULE: THREE PRIME REPAIR 
EXONUCLEASE 1;                           
  22:  3b6o-B  8.3  3.1  127   217   10 PDB  MOLECULE: THREE PRIME REPAIR 
EXONUCLEASE 1;                           
  23:  3b6o-C  8.3  3.0  127   217   10 PDB  MOLECULE: THREE PRIME REPAIR 
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EXONUCLEASE 1;                           
  24:  3b6p-B  8.3  3.1  127   217   11 PDB  MOLECULE: THREE PRIME REPAIR 
EXONUCLEASE 1;                           
  25:  2oa8-B  8.2  3.0  127   226   10 PDB  MOLECULE: THREE PRIME REPAIR 
EXONUCLEASE 1;                           
  26:  1zbu-B  8.0  2.9  125   304   15 PDB  MOLECULE: 3'-5' EXONUCLEASE ERI1;                                     
  27:  1zbu-A  7.9  3.0  127   225   15 PDB  MOLECULE: 3'-5' EXONUCLEASE ERI1;                                     
  28:  1zbh-C  7.9  3.1  129   225   15 PDB  MOLECULE: 3'-5' EXONUCLEASE ERI1;                                     
  29:  1zbh-D  7.8 12.4  157   289   15 PDB  MOLECULE: 3'-5' EXONUCLEASE ERI1;                                     
  30:  1zbh-A  7.8 10.6  149   289   14 PDB  MOLECULE: 3'-5' EXONUCLEASE ERI1;                                     
  31:  1zbh-B  7.8  3.0  128   225   15 PDB  MOLECULE: 3'-5' EXONUCLEASE ERI1;                                     
  32:  1zbu-C  7.8  3.0  127   225   15 PDB  MOLECULE: 3'-5' EXONUCLEASE ERI1;                                     
  33:  2f96-B  7.8  3.6  126   201   13 PDB  MOLECULE: RIBONUCLEASE T;                                             
  34:  2p1j-A  7.7  2.4  111   164   13 PDB  MOLECULE: DNA POLYMERASE III 
POLC-TYPE;                               
  35:  2igi-A  7.7  3.0  126   180   13 PDB  MOLECULE: OLIGORIBONUCLEASE;                                          
  36:  2igi-B  7.7  3.1  126   179   13 PDB  MOLECULE: OLIGORIBONUCLEASE;                                          
  37:  1zbu-D  7.6  3.1  127   224   15 PDB  MOLECULE: 3'-5' EXONUCLEASE ERI1;                                     
  38:  2is3-C  7.6  3.9  128   203   14 PDB  MOLECULE: RIBONUCLEASE T;                                             
  39:  1fxx-A  7.5  2.6  129   459   13 PDB  MOLECULE: EXONUCLEASE I;                                              
  40:  2p1j-B  7.3  2.9  113   171   12 PDB  MOLECULE: DNA POLYMERASE III 
POLC-TYPE;                               
  41:  1yta-D  7.3  3.3  128   180   13 PDB  MOLECULE: OLIGORIBONUCLEASE;                                          
  42:  1yta-C  7.2  3.3  128   180   13 PDB  MOLECULE: OLIGORIBONUCLEASE;                                          
  43:  1yta-B  7.2  3.1  127   180   13 PDB  MOLECULE: OLIGORIBONUCLEASE;                                          
  44:  3cg7-B  7.0  3.0  129   295    8 PDB  MOLECULE: CELL DEATH-RELATED 
NUCLEASE 4;                              
  45:  3cg7-A  7.0  3.0  129   296    8 PDB  MOLECULE: CELL DEATH-RELATED 
NUCLEASE 4;                              
  46:  3cm6-A  7.0  3.1  129   294    8 PDB  MOLECULE: CELL DEATH-RELATED 
NUCLEASE 4;                              
  47:  3cm5-A  7.0  3.1  128   294    8 PDB  MOLECULE: CELL DEATH-RELATED 
NUCLEASE 4;                              
  48:  2is3-D  7.0  3.9  125   203   12 PDB  MOLECULE: RIBONUCLEASE T;                                             
  49:  3cm5-B  6.9  3.1  130   294    8 PDB  MOLECULE: CELL DEATH-RELATED 
NUCLEASE 4;                              
  50:  3cm6-B  6.9  3.1  130   296    8 PDB  MOLECULE: CELL DEATH-RELATED 
NUCLEASE 4;                              
Figure 3.12 A list of the proteins whose Z-score are higher than 2 in Dali database. In the 
first 50 molecules, DNA polymerase III (Epsilon chain), Three prime repair exonuclease 
1(human TREX 1), 3’-5’ exonuclease ERI1, Ribonuclease T, DNA polymerase III POLC-type, 
oligoribonuclease and cell death-related nuclease 4 all show very high similarity to LASV NP 
C-terminal domain. 
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Although the structural comparison from Dali server between influenza A PA N- 
terminal endonuclease domain and C terminal domain of LASV NP shows that there 
is no significant similarity (Table 3.12), the C-terminal domain of LASV NP is 
structural similar to E.coli DNA polymerase III epsilon subunit, RNase T and human 
TREX 1 (Fig. 3.12). All these proteins are 3’-5’ exonucleases. The E.coli DNA 
polymerase III epsilon subunit is responsible for proofreading activity during DNA 
replication by enzymatically excising the incorrect nucleotide(s) from the newly 
synthesised DNA, and RNase T plays an important role in bacterial RNA maturation by 
trimming and modifying the 3’ ends of rRNA and tRNA. TREX1 is a dominant 3’ to 5’ 
exonuclease in mammalian cells, which degrades both ssDNA and dsDNA that are 
released into cytoplasm during apoptosis. Natural mutations of the catalytic residues of 
human TREX1 lead to aberrant accumulation of non-degraded DNAs that are 
recognized by the cellular pattern-recognition receptor to trigger the IFN production, a 
persistently high level of which can lead to autoimmunue diseases, such as 
Aicardi-Goutieres Syndrome and chilblain lupus. We propose that the NP protein 
functionally mimics human TREX1 by removing the viral PAMP RNAs that otherwise 
activate the cellular RNA pattern-recognition receptors to trigger the IFN production. 
The superimposition of LASV NP C-terminal domain and human Trex1 protein (Fig. 
3.13) shows that the centered β sheet described above is highly conserved. 
Particularly, the five catalytic residues from Lassa NP and the Trex1 are at identical 
positions, which further suggest that the LASV NP is a 3’-5’ exonuclease. The human 
Trex1 protein has two Mn
2+
 cations in the active site whereas the C-terminal domain 
 79 
structure contains not only one Manganese cation (black). The electrostatics potential 
map (Fig. 3.14 b) indicates that there is a highly negatively charged cavity, which is a 
typical DEDDH family enzyme. The C-terminal domain of LASV NP ends at residue 
R561, and the rest of residues are disordered. 
 
 
 
Figure 3.13 The superimposition of LASV NP C-terminal domain and human Trex1 
protein. The C-terminal domain of LASV NP is colored in orange with Mn
2+
 colored in black, 
Zn
2+
 colored in blue; The human Trex1protein is colored in green with its two Mn
2+
 colored in 
red. The result shows that the two proteins are very similar. 
 
 
 
 
Table 3.12 Structural comparison of the LASV NP and the influenza A virus PA 
N-terminal endonuclease domain. 
 DALI score* RMS deviation Number of 
aligned C-alpha 
atoms 
Total residues PDB code 
Influenza virus 
PA endonuclease  
1.9 10.4 38 197 3ebj 
* Scores below 2 are not significant. 
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Figure 3.14 Electrostatic surface potential map for the two domain of LASV NP. a, the 
N-terminal domain with highly positively charged cavity colored in blue; b, the C-terminal 
domain with highly negatively charged cavity colored in red, and the black dot represents the 
Mn
2+
. 
 
3.3.2.1    LASV NP structure in complex with Mn
2+
 
3.3.2.1.1    Crystallization of native NP and Mn
2+
 
As described above that the C-terminal domain structure of the LASV NP is very 
similar to 3’-5’ exonucleases, which are metal-dependent enzymes. Normally, 
magnesium and manganese are the most important metals for their activities. To 
check how Mg
2+
 or Mn
2+
 bind on the NP exoribonuclease, we tried to soak Mg
2+
 and 
Mn
2+
 into native NP crystal. Only NP complexed with manganese ion was obtained 
by soaking the crystals in 0.2 M NaCl2, 20% PEG3350 and 15% glycerol containing 
50mM MnCl2. The presence of the manganese and the zinc ions was confirmed by 
fluorescence scanning at the Diamond light sources UK. 
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3.3.2.1.2    Data collection 
The data of the NP and Mn
2+
 complex crystals were collected at IO2 and IO3 of 
Diamond light sources UK with the crystals protected by cryoprotectant that contain 
15% to 20% glycerol, 0.2 M LiCl2, 16% PEG3350. The space group is also P3, the 
unit cell parameters are a = b = 176.81 Å, c = 56.43 Å, α = β = 90° and γ = 120°. The 
data processed to resolution 1.99 Å and the detail statistics are list in table 3.13. 
Table 3.13 Data collection statistics of NP and Mn
2+
 complex: 
Data collection Values 
Wavelength (Å) 0.978 
Resolution (Å)                                        
56.43-1.99 (2.01-1.99) 
Space group 
P3 
Cell dimension (Å, °)                              
a = b = 176.81. c = 56.43 
 
α = β = 90  γ = 120 
No. unique reflections 
134882 (4075) 
Completeness 
99.2 (99.2) 
Redundancy 3.7 (3.3) 
I/σ(I) 
11.8 (2.9) 
 
Rmerge 
0.069 (0.39) 
 
3.3.2.1.3    The NP/Mn
2+
 complex structure determination and refinement 
The NP/Mn
2+
 complex structure was determined by molecular replacement based on 
the native NP crystal structure. After the initial model was built, the refinement and 
 82 
model building were carried out until the Rfactor and Rfree reach 0.179 and 0.214 (Table 
3.14). The Fo-Fc maps were calculated before the ligands zinc and manganese were 
added into the structure. 
Table 3.14 The refinement statistics of NP and Mn
2+
 complex. 
Refinement Mn2+ complex 
Rfactor 0.179 
Rfree 0.214 
Rmsd bonds   
0.02/1.62 
(Å)/angels (°) 
Residues in 
95.84 Ramachandran 
core (%) 
PDB ID 3MWT 
 
The structure was refined and de-twinned by using REFMAC5, and the water 
molecules were added into the structure by ARP/wARP. At last, the structure model 
was evaluated by MolProbity. The model (Fig. 3.15 & 3.16) of LASV NP with Mn
2+
 
was deposited into the PDB with the accession code 3MWT. 
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Figure 3.15 Electron density map for manganese ion that resides within the catalytic 
center of LASV NP protein. The corresponding residues D389, E391, D466, D533 and H528 
are colored in cyan, manganese is colored in marine and the Fo-Fc map at 2.5 σ is colored in 
light blue. 
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Figure 3.16 The crystal structure model of LASV NP protomer in complex with Mn
2+
. 
The N-terminal domain is colored in cyan with the cyan sphere indicating the N terminus; the 
C-terminal domain is colored in orange with the orange sphere i.ndicating the C terminus. 
The black sphere shows Mn
2+
, whereas the blue sphere shows Zn
2+
. The dotted lines represent 
the disordered loops 
 
3.6    Trimeric NP and its interfaces 
There are two different trimeric architectures in crystal lattice that are asymmetric 
trimer and crystallographic three fold axis symmetric trimer (shown in Fig. 3.17). We 
assumed that the native trimeric NP protein forms the symmetric trimer in nature. 
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a b
 
 
Figure 3.17 The asymmetric and symmetric trimeric structures of LASV NP. a, the 
asymmetric trimer with each protomer colored in yellow green, yellow orange and purple 
blue, respectively; b, the symmetric trimer with crystallographic three fold axis symmetry in 
crystal lattice. 
 
There are two forms of interface between every dimerized monomer subunits of these 
two forms trimer architectures, which are tail to tail (N-terminus to N-terminus) for 
asymmetric trimer and head to tail (N-terminus to C-terminus) for symmetric trimer. 
The subnuits in symmetric trimer connect to adjacent monomer in a head to tail 
orientation that forms a ring structure (Fig. 3.18). 
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Figure 3.18 The symmetric trimer of LASV NP in solution. a, the ribbon diagram of LASV 
NP trimer, each of the subunits (labeled as S1,S2 and S3) colored in green, blue and orange, 
respectively; b, the ribbon diagram of symmetrice trimer after 90º rotation along x-axis; c, 
the electrostatic surface potential map of the symmetric trimer shows that the diameter of the 
center hole is around 23Å; d, 90º rotation of the electrostratic surface potential map shows 
that the diameter of the head of the symmetric trimer is around 98Å, whereas the bottom is 
around 118Å. 
 
The interface area between the subunits is 455Å
2
, representing 1.9% of the total 
surface area of a subunit which is 23,343Å
2
. The central hole of the trimeric structure 
is 23Å in diameter, whereas the head ring is 98Å and the body ring is 118Å (Fig. 
3.18). The pridicted residues that  are involved in dimerization on the interfaces 
between each subunit of the symmetric trimer are list in two groups. They are R52, 
K56, K189, Q190 and N230 on N-terminal domain, and D434, D437, N496, D500, 
T510 and K522 on C-terminal domain according to the LIGPLOT result (Brunotte, 
2011) (Fig. 3.19). 
 87 
 
N230	
K522	
K56	 R52	
N496	
D500	
T510	
D437	D434	
K189	
Q190	
N	terminal	domain	
C	terminal	domain	
C/N	interface	
 
Figure 3.19 The interface between each subunit of the symmetric trimer. The residues 
involved in the symmetric trimer on N terminal domain (green) are colored in green, and the 
residues on C terminal domain (grey) are colored in orange. 
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     Chapter 4: Functional study of LASV NP 
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Based on the structural information, several assays were reported in this chapter to 
characterize the functions of LASV NP. From the structure, the C-terminal domain of 
the NP is 3’-5’ exoribonuclease, which may play crucial role in immune suppression, 
and the N-terminal domain can bind cap, which may be involved in cap-snatching. To 
test the functions, NP mutants were made for catalytic residues, zinc binding residues 
and the cap binding residues, and in vitro and in vivo assays were performed. 
 
4.1    Purified LASV NP protein binds RNAs 
LASV nucleoprotein plays an essential role in protecting viral genomic RNA and 
forming ribonucleoprotein (RNP) complex, many purified nucleoproteins of 
negative-strand RNA viruses (Rabies virus, Respiratory Syncytial virus and Vesicular 
Stomatitis virus) contain RNAs from the expression host (Albertini, 2006; MacLellan, 
2007; Todd, 2006). We wondered whether the purified LASV NP contains RNAs from 
the E.coli expression cells. To test this, the LASV NP was loaded on a 2% agarose gel 
and the RNAs were detected as below. 
 
4.1.1    The agarose gel 
A 2 % agarose gel was prepared with TAE buffer. 5µl of RNA loading buffer (6x) was 
added to 15µl purified NP protein. The concentration of the NP protein is 5mg/ml. 
The gel was run for a short time to avoid RNA running off the gel as the RNA size is 
quite small. Briefly, 1 gram agarose powder was added into 100 ml 1× TAE buffer, 
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and the mixture was heated in a microwave oven until the solution became clear. After 
the solution was cooled for 10 minutes, 5µl ethidium bromide (10 mg/ml stock), a 
fluorescent dye, which can intercalate between bases of nucleic acids (DNA and RNA) 
was added. The electrophoresis was carried out under a voltage of 110v for 15 
minutes in 1xTAE buffer. The RNAs were visualized using a UV transilluminator 
(UVP BioDot-IT system). The RNAs that are bound with NP protein are shown as a 
very strong band on the following gel picture (Fig. 4.1), even after so many 
purification steps the RNAs still stay. 
 
 
 
 
 
 
 
Figure 4.1 Electrophoresis gel of the bound RNAs in Z and NP proteins. Lane 1: DNA 
marker; lane 2: monomer Z protein from LASV; lane3: Z protein oligomer; lane4: NP protein. 
 
4.1.2    Denature polyacrylamide gel electrophoresis of RNA      
To determine the length of the bound RNAs in the LASV NP, we decided to use 
urea-denaturing polyacrylamide gel with a single strand RNA standard kit. 20 ml of 
16% polyacrylamide gel was made using 2.0ml 10X TBE, 9.6g urea and 12ml 25% 
acrylamide solution (with gloves, neurotoxin). After adding 10 µl TEMED and 100 µl 
1            2             3           4
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10% fresh ammonium persulfate to the gel solution, The gel solution mix was swirled 
gently, and then quickly pour into the gel plate without any bubbles. The comb was 
put into the top of the gel leaving the gel to polymerize for about 1 hour in a Bio-RAD 
gel cassette. 
 
Once the gel was polymerized, the comb was removed and the gel cassette was put 
into the reservoir. The gel was pre-run in 1× TBE for 35 minutes to remove some 
contaminants. The sample was prepared with 15µl of the purified NP protein and 5µl 
of the formamid loading buffer, and then heat at 90°C for 5 minutes. The 
electrophoresis was carried out for 1.5 hrs and the RNA gel was stained in 0.04% EB 
containing 1× TBE for 20 min. The RNAs were visualized using the UV 
transilluminator. 
 
 The gel showed that there are two main bands of the bound RNAs, corresponding to 
120 bp and 100 bp respectively (Fig. 4.2). As the RNAs are from the host E.coli cells 
and they are nonspecific binding, it is not surprised that the lengths of the RNA are 
different. Although the NP is a 3’-5’ exoribonuclease, this result indicates that the NP 
protein can protect the RNAs from the exonuclease. 
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Figure 4.2 Denaturing eletrophoresis gel of NP-RNA complex. Lane 1: NP protein with 
RNA; lane 2: RNA marker. 
 
 
 
4.2    Characterization of the 3’-5’ exoribonuclease of LASV NP 
       C-terminal domain 
   
4.2.1    The LASV NP is a 3’-5’ nuclease 
The LASV NP structure and the NP in complex with Mn2+ have shown that the 
LASV NP is a 3’-5’ nuclease, belonging to DEDDh subfamily with the catalytic 
residues D389, E391, D466, H528 and D533. Interestingly, Residue D389 is proven 
to be crucial for immune suppression (corresponding to D382 with LCMV/NP, 
Martínez-Sobrido, 2009). 
 
In order to determine the residues which are key for the 3’-5’ exoribonuclease 
function that leading to the suppression of type I interferon. In vitro and in vivo assays 
were performed. The catalytic residues D389, E391, G392, D466, H528 and D533 
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that reside around Mn
2+
 and are conserved in all arenavirus, which indicates that the 
catalytic residues are essential (Fig. 4.3).  
 
             
Figure 4.3 The nuclease active site of C-terminal domain of NP and the related residues. 
Mn
2+
 is colored in pink, residue G392 is colored in green, and the rest residues are D389, 
E391, D466, H528 and D533. 
 
4.2.2    Generation of catalytic residue mutants of LASV NP 
4.2.2.1    Mutants primers design and molecular cloning 
The substitution of the catalytic residues D389A, E391A, G392A, D466A, H528A, 
C529A, D533A by alanine were performed according to the modified protocol from  
QuikChange
TM
 (Liu, 2008). 
 
To increase the PCR efficiency, the designed primers contain 22 to 25 bases of 
non-overlapping region at its 3’ end and 19 to 21 bases of the overlapping region at its 
primer to primer complementary 5’ end (Fig. 4.4) depending on each mutants, thus the 
melting temperature for the non-overlapping region is 9°C to 12°C higher than the 
overlapping region (see Appendix I.3 for the mutants primers). These newly designed 
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primers decrease the self-annealing of the complementary primers and help to bridge 
the strand break of the newly synthesized DNA from the first PCR cycle which will 
be used as template for next cycle of the PCR reaction. As the parental templates were 
methylated, which will be removed by DpnI, and the newly synthesized DNA 
containing the mutations will be transformed into DH5α competent cells.  
      
 
Figure 4.4 Primer designed for site directed mutants of LASV NP. The primers contain 3’ 
end non-overlapping region with the melting temperature is around 59°C and 5’ overlapping 
region with the melting temperature is around 49°C. The mutated site is located on the 
overlapping region. 
 
The 50ul PCR water solution contains 2-10 ng template, 1uM forward primer, 1uM 
reverse primer, 200 uM dNTPs and 3 units Pfu DNA polymerase. The reactions were 
started with 95°C for 5 minutes, then 12 cycles of amplification. Each of the cycles 
contains 95°C for 1 minute, annealing for 1 minute and 72°C for 18 minutes from 
extension. All the mutants were confirmed by DNA sequencing.  
 
4.2.2.2    Mutant proteins expression and purification 
The mutant proteins D389A, E391A, G392A, D466A, H528A and D533A which are 
putative catalytic residues are expressed and purified as native NP described in 
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previous chapter (Fig. 4.5-4.10). They all show two forms of oligomers that are 
hexamer and trimer, based on the elution volume of the target protein. 
 
I.    The NP D389A mutant expression and purification 
The mutant D389A was expressed and purified using similar methods as the native NP. 
Briefly, the Rosetta cells that contains the target mutant gene NP D389A plasmid were 
innocated into 10 liters of LB medium in present of 50 μg/ml Ampcilin and 34 μg/ml 
chloramphenicol (Duchefa Biochemic) at 37°C, and the protein was induced by 
0.03mM IPTG when the OD600 of the cell cultures reached to 0.6. The NP protein was 
induced overnight at 20°C. The cells were harvested, and the cells were broken by 
sonication. The fusion protein was purified by amylose resin, and the MBP was 
removed by TEV cleavage. The D389A mutant protein is finally purified by a gel 
filtration column (Fig. 4.5 top), showing that the first peak is NP which is separated 
from MBP according to the size difference. To test the purity, each fraction was 
loaded on a SDS-PAGE (Fig. 4.5 bottom). 15mg of the purified trimeric NP D389A 
mutant protein was obtained from 10-liter cultures.  
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Figure 4.5 The gel filtration chromatograph and the SDS-PAGE gel picture of the 
purified NP mutant protein D389A. 
 
 
II.    The NP E391A mutant protein expression and purification 
The mutant E391A protein was expressed and purified using similar methods as 
mutant D389A that is described above. The E391A mutant is finally purified by gel 
filtration column (Fig. 4.6 top), and the purity was test by a SDS-PAGE gel (Fig. 4.6 
bottom). 7mg of the purified trimeric NP E391A mutant protein was obtained from 10 
liters of culture.  
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Figure 4.6 The gel filtration chromatograph and the SDS-PAGE gel picture of the 
purified NP mutant protein E391A. 
 
 
III.    The NP G392A mutant protein expression and purification 
The mutant G392A was expressed and purified using similar methods as mutant 
D389A that is described above. The G392A mutant is finally purified by a gel 
filtration column (Fig. 4.7 top), and the purity was checked by a SDS-PAGE gel (Fig. 
4.7 bottom). 6mg of the purified trimeric NP G392A mutant protein was obtained 
from 10 liters of culture. 
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Figure 4.7 The gel filtration chromatography and the SDS-PAGE gel picture of the 
purified NP mutant protein G392A. 
 
IV.    The NP D466A mutant protein expression and purification 
The mutant D466A was expressed and purified using similar methods as mutant 
D389A that is described above. The D466A mutant is finally purified by gel filtration 
column (Fig. 4.8 top), and the purity was determined by a SDS-PAGE gel (Fig. 4.8 
bottom). 10mg of the purified trimeric NP D466A mutant protein was obtained from 
10 liters of culture.  
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Figure 4.8 The gel filtration chromatography and the SDS-PAGE gel picture of the 
purified NP mutant protein D466A. 
 
V.    The NP H528A mutant protein expression and purification 
The mutant H528A NP was expressed and purified using similar methods as mutant 
D389A that is described above. The H528A mutant NP is finally purified by a gel 
filtration column (Fig. 4.9 top), and the purity was checked by a SDS-PAGE gel 
(Fig.4.9 bottom). 12mg of the purified trimeric NP H528A mutant protein was 
obtained from 10 liters of culture.  
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Figure 4.9 The gel filtration chromatograph and the SDS-PAGE gel picture of the 
purified NP mutant protein H528A. 
 
VI.    The NP D533A mutant NP expression and purification 
The mutant D533A NP was expressed and purified using similar methods as mutant 
D389A that is described above. The D533A mutant is finally purified by a gel 
filtration column (Fig. 4.10 top), and the purity was tested by a SDS-PAGE gel (Fig. 
4.10 bottom). 15mg of the purified trimeric NP D533A mutant protein was obtained 
from 10 liters of culture.  
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Figure 4.10 The gel filtration chromatograph and the SDS-PAGE gel picture of the 
purified NP mutant protein D533A. 
 
4.2.3    Quanternary structures of the NP mutants D389A, E391A and D466A 
All these three NP mutants D389A, E391A and D466A share the identical quanternary 
structure with native NP. Although these purified mutants bind more RNAs than 
native NP, which prohibited us to compare their quaternary structures by circular 
dichroism spectroscopy. The gel filtration graphs (Fig. 4.11) strongly suggest that the 
mutants fold properly as the native NP. This is further confirmed by our functional 
LASV minigenome assay showing that all the three mutants had the similar 
transcriptional activities as the native NP. 
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Figure 4.11 Gel filtration chromatographs of the WT and mutant LASV NP proteins. 
The gel filtration chromatography was performed using a column Hiload 16/60 Superdex 200 
(GE healthcare) and AKTAxpress (GE healthcare). The first peak is the hexameric and the 
second peak is the trimeric LASV NP. The third peak is MBP. D389A (green line), E391A 
(orange line), D466A (grey line) and WT (blue line). 
 
4.2.4    The in vitro activity determination of the 3’-5’ exoribonuclease 
As above, the structural information of the NP protein indicated that LASV NP is a 
3’-5’ exoribonuclease. To test this hypothsis, in vitro assays of RNA degradation were 
performed using both native and mutated NP proteins.  
 
4.2.4.1    LASV NP degrades double strand DNAs 
The experiment was carried out with 1kb dsDNA ladder which was incubated at 37ºC 
for an hour in the presence of 10 mM EDTA as control 1, 1kb dsDNA ladder and 
10mM EDTA together with trimeric NP protein as control 2, 1kb dsDNA ladder and 
10mM MnCl2 together with trimeric NP protein in line 3, and 1kb dsDNA ladder with 
10mM MnCl2 together with hexameric NP protein in line4 (Fig. 4.12). The dsDNA 
ladders were digested and then separated on 1% agarose gel, and the gel was stained 
by ethidium bromide. The digestion result shows that with the presence of Mn
2+ 
both 
the trimeric and hexameric NPs can degrade dsDNA. 
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Figure 4.12 Both trimeric and hexameric LASV NP proteins degrade double strand 
DNA. Lane 1, control 1, DNA ladder in presence of EDTA; lane 2, control 2, DNA ladder, 
EDTA and trimeric NP; lane 3, DNA ladder, MnCl2 and trimeric NPs; lane4, DNA ladder, 
MnCl2 and hexameric NPs.  
 
4.2.4.2    LASV NP degrades both ssRNA and dsRNA 
In order to test the 3’-5’ ribonuclease activities, different RNA substrates were 
prepared as below:  
 
4.2.4.2.1    In vitro chemical and biological RNA synthesis 
To synthesize single strand RNAs in vitro, the 30-nucleotide cRNA (sense) sequence 
5’-CUGGGCUUACCUAUUCUCAGCUGAUGACCC-3’ was derived from the 
LASV NP (Josiah strain) S segment (nucleotides 2186–2215 in antigenomic 
orientation) and chemically synthesized by Eurogenes. The 30-nucleotide vRNA (in 
genomic orientation) sequence  
5’-GGGUCAUCAGCUGAGAAUAGGUAAGCCCAG-3’ was complementary to the 
cRNA. The cRNA (30 nucleotides) was used as one of the three substrates for 
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3’–5’exoribonuclease assay. The 5’-triphosphorylated vRNA was generated by in 
vitro transcription of the partial dsDNA template formed by the T7 promoter sequence 
5’-AATTTAATACGACTCACTATAGG-3’ and the reverse complement of the T7 
promoter sequence and of the LASV (Josiah strain) S segment (nucleotides 
2186–2215)  
5’-CTGGGCTTACCTATTCTCAGCTGATGACCCTATAGTGAGTCGTATTAAATT-
3’ 
using the T7 MEGAshortscript kit following the manufacturer’s instructions 
(Ambion). A similar strategy was used to generate the 32-nucleotide triphosphorylated 
cRNA with the T7 primer and LASV (Josiah strain) S segment (nucleotides 
2186–2213) 
5’-GGGTCATCAGCTGAGAATAGGTAAGCCCAGCCTATAGTGAGTCGTATTAA
ATT-3’. A similar strategy was used to generate the 60-nucleotide vRNA 
corresponding to LASV (Josiah strain) S segment (nucleo- tides 2186–2213), using 
the partial dsDNA template formed by 5’-AATTTAATACGACTCACTATAGG-3’ and  
5’-GTAAATCCCTGCAGTCGGCAGGGTTTACCGCTGGGCTTACCTATTCTCAG
CTGATGACCCTATAGTGAGTCGTAT TAAATT-3’ as the template. To synthesize 
the capped viral mRNA transcripts corresponding to nucleotides 992–1117 of the 
LASV NP gene, the DNA template was PCR amplified from the NP expression 
plasmid with a forward primer  
5’-AATTTAATACGACTCACTATAGGGAAAACACTGTCGTTGATCTGGAATC- 
3’ (underlined are T7 promoter sequences) and a reverse primer  
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5’-GGGTCATCAGCTGAGAATAGGTAAGCCCAGCGG-3’, and subjected to in 
vitro RNA synthesis using the mMESSAGE mMACHINE T7 Ultra kit (Ambion) 
following the manufacturer’s instruction, except that no poly(A) tail was added (see 
Appendix I.4). 
 
To obtain the blunted dsRNA (5’-OH dsRNA), both chemically synthesized 30 
nucleotide unphosphorylated cRNA and vRNA oligonucleotides were dissolved into 
0.1 M NaCl, 1 mM EDTA and 0.1 M Tris pH 8.0 at the final concentration of 200 mM, 
and an equal amount of the two oligonucleotides was mixed together and annealed in 
a thermo-cycler as follows: 95ºC for 3 min, 68ºC for 1 min and then 4ºC. To 
generate the double 5’-triphosphorylated dsRNA, equal amounts of the 
triphosphorylated 5’ppp-vRNA and 5’ppp-cRNA were annealed in vitro. To make the 
singly 5’-triphosphorylated dsRNA, equal amounts of the in vitro synthesized 
32-nucleotide 5’ppp-vRNA and the chemically synthesized 30-nucleotide 
unphosphorylated cRNA were annealed in vitro (see Appendix I.5).  
 
The human 18S rRNA fragment (128 nucleotides) was generated by a T7 RNA 
polymerase directed in vitro RNA synthesis reaction, using the pTRI-RNA 18S 
control plasmid (Ambion), following the manufacturer’s instruction. A plasmid 
phRL-CMV that encodes the T7 promoter (T7p)-directed human β-globin gene was 
provided by R. Elliott and G. Blakqori. The T7 β-globin DNA fragment was purified 
by agarose electrophoresis after digestion of the phRL-CMV plasmid with HindIII 
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and Smal. The capped human globin mRNA transcripts were generated using the 
T7p-globin fragment as a template and the mMESSAGE mMACHINE T7 Ultra kit 
from Ambion, and the poly(A) tail was added following the manufacturer’s 
instruction. 
 
The ssRNA markers (perfect RNA markers, 0.1–1 kb) were purchased from Novagen. 
The low molecular mass ssRNA marker (10–100 nucleotides) was purchased from 
USB. The dsRNA ladder (21–500 bp) was purchased from New England Biolabs. 
 
4.2.4.2.2    The LASV NPs degrade single strand RNA 
The first experiment was carried out in 12 ul reaction solution containing 2ul RNA 
ladder with the size range from 0.1kb to 1kb (perfect RNA markers, Merck). The 
reaction solutions were incubated with or without 7 ug NPs in 0.3 M NaCl, 10% 
glycerol and 20 mM Tris pH 7.5 and 10mM MnCl2 at 37ºC for a time course of 20 
minutes, 40 minutes and 80 minutes, and the three controls were incubated for 80 
minutes. All these reactions were stopped by adding EDTA to a final concentration of 
20mM. The samples were mixed with equal volumes of RNA loading buffer 
(Ambion), heated at 95 ºC for 3 min, cooled on ice for 5 min, and separated in 6% 
polyacrylamide gel containing 8M. The gels were stained in 0.05% ethidium bromide 
for 25 min, visualized using the 2UV transilluminator (UVP). The gel result shows 
that LASV NP degrades different size of ssRNA on the range of 0.1 to 1kb (Fig. 4.13). 
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Figure 4.13 Lassa NP protein degrades different size of ssRNA. Lane1, control 1, EDTA; 
lane2, control 2, EDTA and NP; lane3, control 3, NP; lane 4, NP, MnCl2 with 20 minutes 
incubation; lane5, NP, MnCl2 with 40 minutes incubation; lane6, NP, MnCl2 with 60 minutes 
incubation. 
 
To test whether the LASV NP can discriminate viral RNA (vRNA), viral 
complementary RNA (cRNA) and viral message RNA (mRNA), we mixed those three 
substrates together and did the in vitro cleavage assays. The activities of the NP native 
and three catalytic residue mutants D389A, E391A and D466A were determined as 
shown in figure 4.14. The capped viral mRNA contains 126nt, showed as the top lane; 
the viral genomic sense RNA contains 60nt, showed as the middle lane; the 
complementary antigenomic sense RNA contains 30nt, showed as the bottom lane. 
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These ssRNA substrates were incubated at 37°C for one hour unless otherwise stated 
(line 4). The samples were then separated on 15% PAGE gel containing 8M urea. 
Both trimeric and hexameric WT NPs degrade these three ssRNA substrates even with 
30 minutes incubation of trimeric NPs. But the trimeric mutants D389A, E391A and 
D466A show significant reduction of the RNase activity in vitro (Fig. 4.14). Control 1 
is the mixed of the three ssRNAs without NP, whearas control 2 shows the ssRNA 
substrates with WT trimeric NP in the presence of 10mM EDTA.  
 
 
Figure 4.14 Both trimeric and hexameric WT NPs but not its catalytic mutants degrade 
ssRNA. Lane 1, RNA ladder; lane 2, control 1, ssRNA substrate without NP; lane 3, control 2, 
ssRNA, WT NP and 10mM EDTA; lane 4, ssRNA, WT NP for 30 minutes incubation; lane 5, 
ssRNA and WT NP for 60 minutes incubation; lanes 6-8, ssRNA, trimeric NP mutants D389A, 
E391A and D466A; lane 9, WT hexameric NP. The ssRNA substrates contain capped mRNA, 
cRNA and vRNA, which were marked as above. 
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LASV NPs degrade various cellular RNAs with a priority of shorter one. The 
comparision of the degradation efficiency between 128nt 18s rRNA and human 
β-globin mRNA was shown in figure 4.15. The β-globin mRNA was synthesized by 
an in vitro transcription reaction using mMESSAGE mMACHINE T7 ultra kit 
(Ambion), which incorporated the 5’cap analogue and 3’ polyA sequence. The human 
18S rRNA fragment was in vitro transcribed using the MEGAshortscript kit (Ambion) 
from the supplied control template. The controls are in present of 10 mM EDTA. 
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Figure 4.15 The comparision of the LASV NPs in degrading between 18s rRNA and 
human β-globin mRNA. a, the degradation level of human β-globin mRNA by either WT 
LASV NPs or its catalytic mutants; b, the degradation level of 18s rRNA by either WT LASV 
NPs or its three catalytic mutants. 
 
4.2.4.2.3    LASV NP degrades double strand RNA 
Further experiments were carried out to determine whether the WT LASV NP can  
degrade various sizes of double stranded RNA substrates. The first substrates were a 
dsRNA ladder which is from 21 to 500 bp (dsRNA ladder, New England Biolabs) (Fig. 
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4.16). 2ul of the dsRNA ladder was added to each of the reaction solutions that were 
incubated for 60 mins unless otherwise stated, with and without NP (WT or D389A 
mutant), EDTA, or MnCl2, and separated by a 2% agarose gel. 
              
C 1         C 2       3 0 m i n s    6 0 m i n s   D 3 8 9 A       
1           2             3            4           5
 
Figure 4.16 LASV NP degrades various sizes of dsRNA substrates. Lane 1, control 1, 
EDTA; lane 2, control 2, EDTA and WT NP; lane 3, WT NP and MnCl2 for 30 mins 
incubation; lane 4, WT NP and MnCl2 for 60 mins incubation; lane 5, NP mutants D389A and 
MnCl2 for 60 mins. 
  
LASV NP degrades dsRNAs regardless whether the dsRNA contains a 5’ hydroxyle 
(5’-OH), or single triphosphaorylated 5’ (5’ppp/5’-OH) or double triphosphorylated 5’ 
(5’ppp/5’ppp) (Fig. 4.17). Although it also digests the long dsRNA mimic poly (I:C) 
(Fig. 4.18), the degradation efficiency is not as good as the shorter dsRNAs. 
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Figure 4.17 LASV NP degrades various dsRNAs. These dsRNAs contain 5’ hydroxyl 
dsRNA (5’-OH) (top), or single 5’ triphosphaorylated dsRNA (5’ppp/5’-OH) (bottom) or 
double 5’ triphosphorylated dsRNA (5’ppp/5’ppp) (middle). 
 
 
 
 
Figure 4.18. LASV NP degrades long dsRNA mimic poly (I:C). Lane 1, control without NP 
for 80 minutes incubation; lane 2, WT NP and poly (I:C) for 20 minutes incubation; lane 3, 
WT NP and poly (I:C) for 40 minutes; lane 4, WT NP and poly (I:C) for 80 minutes 
incubation; lane 5, poly (I:C) and mutant NP E391A for 80 minutes incubation; lane 6, poly 
(I:C) and mutant NP D466A for 80 minutes incubation; lane 7, poly (I:C) and mutant NP 
D389A for 80 minutes incubation. 
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4.2.4.3    The 3’-5’ exoribonuclease activity is divalent cation dependent 
3’-5’ exonuclease is a metal dependent enzyme, and our structural studies have shown 
that the manganese is also found in the catalytic center of the crystal structure of 
LASV NP. Mn
2+
 is assumed to be essential for the RNase reaction. To check which 
metal ion is the best for the activity, we tested the RNA degradation efficiency with 
different divalent cations. The activity order of them is: 
Mn
2+
>Co
2+
>Mg
2+
>Ca
2+
>Zn
2+
>Fe
2+
>Ni
2+
>Cu
2+
 (Fig. 4.19). In this experiment, three 
ssRNA substrates were mixed and incubated with the WT LASV NP protein at 37°C 
for 80 min (unless otherwise stated) in the presence of 10 mM EDTA (for control) or 
10 mM of the respective divalent cation ions.   
control    Mn2+ 20   Mn2+ 80      Co2+ Mg2+ Fe2+ Ca2+ Zn2+ Ni2+ Cu2+
1            2            3            4          5          6           7           8           9           10
mRNA
cRNA
vRNA
 
Figure 4.19 LASV NP is a divalent cation dependent 3’-5’ exoribonuclease. All the 
samples were incubated with WT LASV NP and three ssRNA substrates. Lane 1, control, 
EDTA; lane 2, Mn
2+
, 20 minutes; lane 3, Mn
2+
, 80 minutes; lanes 4-10, Co
2+
, Mg
2+
, Fe
2+
, Ca
2+
, 
Zn
2+
, Ni
2+
, Cu
2+
, 80 minutes. 
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4.2.5    The zinc binding site of LASV NP 
4.2.5.1    The zinc finger of LASV NP 
Although during expression and purification, no zinc compounds were added, a zinc 
ion which is presented within C-terminal domain near the 3’-5’ exoribonuclease 
active site, which was confirmed in the structure by fluorescence scanning analysis 
(Fig. 4.20). The residues that coordinate the zinc ion were E399A, C506A, H509A 
and C529A. The zinc finger fold domain is well known as the DNA-binding or 
RNA-binding site of the zinc finger protein. In the NP structure, the zinc binding 
residues are atypical CCHE (Fig. 4.20).  
                                       
 
 
Figure 4.20 The zinc-binding site of LASV NP. The zinc ion is coordinated by residues 
E399A, H509A, C506A, and C529A. The zinc ion-binding site is very close to the Mn
2+
 
binding site. Zn
2+
 is shown as a blue sphere and Mn
2+
 in black.  
 
4.2.5.2    The NP mutants of zinc binding residues 
The four NP mutants at zinc binding site were generated to test the RNA binding 
affinity (the result does not shown in this thesis) by using the similar mutagenesis as 
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descripted above, and the mutants were confirmed by DNA sequencing. 
 
I.    The NP E399A mutant protein expression and purification 
The mutant E399A NP was expressed and purified using similar methods as the native 
NP. Briefly, the expression cells containing the target mutant gene NP E399A was 
innoculated into 10 liters of LB medium in present of 50 μg/ml Ampcilin and 34 
μg/ml chloramphenicol (Duchefa Biochemic) at 37°C, and the protein was induced by 
0.03mM IPTG when the OD600 of the cell culture reached to 0.6. The NP mutant 
protein was induced overnight at 20°C. The cells were harvested, and the cells were 
brokend by sonication, and the fusion protein was purified by amylose resin. After tev 
cleavage and removing MBP, the E399A mutant protein is finally purified by a gel 
filtration column (Fig. 4.21 top), showing that the first peak is NP which is separated 
from MBP according to the size difference. To test the purity, each fraction was 
loaded on a SDS-PAGE (Fig. 4.21 bottom). 0.3mg of the purified trimeric NP E399A 
mutant protein was obtained from 10 liters of culture.  
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Figure 4.21 The gel filtration chromatograph and the SDS-PAGE gel picture of the 
purified NP mutant protein E399A. 
 
II.    The C506A mutant NP expression and purification 
The NP mutant C506A was expressed and purified using similar methods as mutant 
E399A that is described above. The NP C506A mutant is finally purified by a gel 
filtration column (Fig. 4.22 top), and the protein purity was tested by a SDS-PAGE 
gel (Fig. 4.22 bottom). 0.2mg of the purified trimeric NP C506A mutant protein was 
obtained from 10 liters of culture.  
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Figure 4.22 The gel filtration chromatograph and the SDS-PAGE gel picture of the 
purified NP mutant protein C506A. 
 
III.    The NP H509A mutant protein expression and purification 
The NP mutant H509A was expressed and purified using the similar methods as 
mutant E399A described above. The NP H509A mutant is finally purified by a gel 
filtration column (Fig. 4.23 top), and the protein purity was checked by a SDS-PAGE 
gel (Fig. 4.23 bottom). 0.1mg of the purified trimeric NP H509A mutant protein was 
obtained from 10 liters of culture.  
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Figure 4.23 The gel filtration chromatograph and the SDS-PAGE gel picture of the 
purified NP mutant protein H509A. 
 
IV.    The NP C529A mutant protein expression and purification 
The NP mutant C529A was expressed and purified using the similar methods as 
mutant E399A described above. The C529A mutant is finally purified by a gel 
filtration column (Fig. 4.24 top), and the purity was checked by a SDS-PAGE gel (Fig. 
4.24 bottom). 0.1mg of the purified trimeric NP C529A mutant protein was obtained 
from 10 liters of culture.  
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Figure 4.24 The gel filtration chromatograph and the SDS-PAGE gel picture of the 
purified NP mutant protein C529A. 
  
 
4.2.6    The in vivo functional assays of LASV NP C-terminal domain 
To probe the significance of the function of NP’s exoribonuclease in suppression of 
type I IFN-β production, five putative catalytic residues D389A, E391A, D466A, 
D533A and H528A were substituted by alanine, along with the WT NP, were sent to 
our collaborators at Emory University for the luciferase reporter gene based assay and 
to examine whether NP’s exoribonuclease activity is required for suppression of type I 
IFN (Fig. 4.25) (Qi, 2010).  
 
Firstly, we tested whether the mutants affect the viral RNA transcription using a 
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minigenome assay. The assay was carried out with WT NP and its mutants 
transcribing the LASV RNA that encoding a Renilla luciferase reporter gene, the 
mammalian cell expression vector contain either native or Myc tagged NP gene. The 
expression level of the proteins in mammalian cell which were shown in figure 4.25a 
(top) indicates neither the tags nor the mutations altered the overall structure of NP. 
The similar increased fold of Renilla luciferase activities between WT NP and its 
mutants also proved that the mutations did not affect NP’s function in mediating viral 
RNA transcription (Fig. 4.25a bottom).  
 
To determine the role of LASV NP in immune evasion, serial experiments were 
carried out by co-transfecting the 293T cells with the vectors of WT NP and a group 
of catalytic residues that residues were substituted with alanine, the vectors contain 
both firefly luciferase reporter gene and the functional promoter sequence IFN-β gene 
(pIFN β-Luc), and the plasmid of β-gal to normalize the transfection efficiency. The 
aim is to reveal the inhibition of IFN-β activation by NP or its mutants. The fold 
induction of luciferase activity over the control shows that LASV WT NP but not its 
five catalytic mutants exhibit suppressive activity of either Sendai-virus induced or 
immunostimulatory Pichinde-virion-associated RNAs/ poly(I:C) induced IFN-β 
activation (Fig. 4.25b,c). 
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Figure 4.25 The exoribonuclease activity of NP is important for blocking the IFN 
induction. a, the NP catalytic mutants were expressed at the similar levels to the wild type in 
mammalian cells and had the similar transcriptional activities in the LASV minigenome assay; 
b, the NP catalytic mutants were defective in suppressing the Sendai-virus (SeV)-induced IFN 
induction by a LUC-based IFN-β promoter assay; c, the NP catalytic mutants were defective 
in suppressing the IFN production induced by the immunostimulatory RNAs poly(I:C) and 
Pichinde-virion-associated RNAs. 
 
 
 
4.3    The cap binding cavity on N-terminal domain of LASV NP 
4.3.1    The complex structure of the UTP/dTTP and LASV NP 
The N-terminal domain has a novel fold, showing a deep cavity (Fig. 4.26). To 
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investigate the function of the cavity, both the dTTP and UTP compounds were 
incubated with WT NP at 20mM final concentration for 30 mins on ice, and the NP in 
complexes with dTTP and UTP were obtained. The structures were determined as 
described in the last chapter. The superimposition of the complex shows the 
triphosphate of UTP was bound in the same manner as that of dTTP at the deep cavity 
of LASV NP. The original Fo-Fc map contoured at 2.5 σ for both dTTP and UTP. 
 
                  
Figure 4.26 Superimposition of the UTP-NP and dTTP-NP complexes. The original Fo-Fc 
map of the triphosphate of UTP is shown in blue, with the carbon atoms of UTP shown in 
magenta and those of dTTP in orange. The deep cavity residues are colored in yellow, the 
entrance cavity residues are colored in green.  
 
The triphosphate group of dTTP/UTP was anchored by salt bond formed with side 
chains of the conserved residues K253A, R300A, R323A and K309A. The 
hydrophobic pocket is composed of residues F176A, W164A, L172A, M54A, I241A, 
L120A and L239A. The entrance region is formed by hydrophobic residues Y319A, 
Y209A, Y213A, L265A and the acidic residue E266A. The acidic amino acid is 
known for base binding, the entrance cavity probably anchored one nucleotide from 
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the host mRNA. Unlike the cap snatching mechanism in influenza A virus, when PB2 
hold the cap structure of the cellular mRNA, PA acts as the endonuclease to cleave the 
mRNA and leave 10-12 nucleotide after the cap, exposed outside the protein, the cap 
structure m
7
G along with at least one more nucleotide are embedded within the deep 
cavity in NP. Although more evidence should be provided, the hydrophobic thymidine 
binding pocket is assumed to be the cap binding site for the cap snatching mechanism 
in Arenaviridae family. 
 
4.3.2    Expression and purification of the LASV NP mutants 
The NP mutants M54A, E117A, L120A, W164A, F176A, Y209A, K253A, E266A, 
R300A, K309A, Y319A, R323A that located around the deep cavity on N-terminal 
domain were generated as previously described to send for the surface plasmon 
resonance (SPR) experiment to identify the binding affinity between NP and various 
cap analogues (the experiment data does not shown in this thesis). These mutants 
were purified and prepared for further experiments. The gel filtration results are 
shown in figure 4.27- 4.38. 
 
I.    The NP M54A mutant expression and purification 
The NP mutant M54A was expressed and purified using similar methods as the native 
NP. Briefly, the expression plasmid that contains the target mutant gene NP M54A 
was incubate in 10 liters of LB medium in present of 50 μg/ml Ampcilin and 34 μg/ml 
chloramphenicol (Duchefa Biochemic) at 37°C, and the mutant protein was induced 
 124 
by 0.03mM IPTG when the OD600 of the cell culture reached to 0.6. The NP protein 
was induced overnight at 20°C. The cells were harvested, and the cells were broken 
by sonication. The fusion protein was purified by amylose resin. After TEV cleavage 
and removing MBP, the NP M54A mutant is finally purified by a gel filtration column 
(Fig. 4.27 top), which showed that the first peak is NP and the second peak is MBP. 
To test the protein purity, each fraction was loaded on a SDS-PAGE (Fig. 4.27 
bottom), and the 12mg of the purified trimeric NP M54A mutant protein was obtained 
from 10 liters of culture.  
 
Figure 4.27 The gel filtration result and SDS-PAGE gel of the NP M54A mutant that is 
located around the deep cavity in N-terminal domain. 
 
 
II.    The NP E117A mutant expression and purification 
The NP mutant E117A was expressed and purified using the similar methods as NP 
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mutant M54A described above. The E117A mutant is finally purified by a gel 
filtration column (Fig. 4.28 top), and the protein purity was determined by a 
SDS-PAGE gel (Fig. 4.28 bottom). 10mg of the purified trimeric NP E117A mutant 
protein was obtained from 10 liters of culture.  
 
 
 
Figure 4.28 The gel filtration chromatograph and the SDS-PAGE gel of the NP E117A 
mutant. 
 
III.    The NP L120A mutant expression and purification 
The NP mutant L120A was expressed and purified using similar methods as mutant 
NP M54A described above. The NP L120A mutant is finally purified by a gel 
filtration column (Fig. 4.29 top), and the purity was tested by a SDS-PAGE gel (Fig. 
4.29 bottom). 12mg of the purified trimeric NP L120A mutant protein was obtained 
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from 10 liters of culture.  
 
 
 
Figure 4.29 The gel filtration chromatograph and the SDS-PAGE gel of the NP L120A 
mutant. 
 
IV.    The NP W164A mutant expression and purification 
The NP mutant W164A was expressed and purified using the similar methods as the 
NP mutant M54A described above. The W164A mutant is finally purified by a gel 
filtration column (Fig. 4.30 top), and the purity was tested by a SDS-PAGE gel (Fig. 
4.30 bottom). 16mg of the purified trimeric NP W164A mutant protein was obtained 
from 10 liters of the cell culture. 
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Figure 4.30 The gel filtration chromatograph and the SDS-PAGE gel of the NP W164A 
mutant. 
 
V.    The NP F176A mutant expression and purification 
The NP mutant F176A was expressed and purified using similar methods as the NP 
mutant M54A described above. The NP F176A mutant is finally purified by a gel 
filtration column (Fig. 4.31 top), and the purity was tested by a SDS-PAGE gel (Fig. 
4.31 bottom). 8mg of the purified trimeric NP F176A mutant protein was obtained 
from 10 liters of culture. 
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Figure 4.31 The gel filtration chromatograph and the SDS-PAGE gel of the NP F176A 
mutant. 
 
 
VI.    The NP Y209A mutant expression and purification 
The NP mutant Y209A was expressed and purified using the similar methods as the 
NP mutant M54A described above. The Y209A mutant is finally purified by gel 
filtration chromatography (Fig. 4.32 top), and the protein purity was checked by a 
SDS-PAGE gel (Fig. 4.32 bottom). 12mg of the purified trimeric NP Y209A mutant 
protein was obtained from 10 liters of culture. 
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Figure 4.32 The gel filtration chromatograph and the SDS-PAGE gel of the NP Y209A 
mutant. 
 
VII.    The NP K253A mutant expression and purification 
The NP mutant K253A was expressed and purified using the similar methods as the 
NP mutant M54A described above. The NP K253A mutant is finally purified by a gel 
filtration column (Fig. 4.33 top), and the protein purity was checked by a SDS-PAGE 
gel (Fig. 4.33 bottom). 17mg of the purified trimeric NP K253A mutant protein was 
obtained from 10 liters of culture. 
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Figure 4.33 The gel filtration chromatograph and the SDS-PAGE gel of the NP K253A 
mutant. 
 
 
VIII.    The NP E266A mutant expression and purification 
The NP mutant E266A was expressed and purified using the similar methods as the 
NP mutant M54A described above. The E266A mutant is finally purified by a gel 
filtration column (Fig. 4.34 top), and the protein purity was determined by a 
SDS-PAGE gel (Fig. 4.34 bottom). 7mg of the purified trimeric NP E266A mutant 
protein was obtained from 10 liters of culture. 
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Figure 4.34 The gel filtration chromatograph and the SDS-PAGE gel of the NP E266A 
mutant. 
 
 
IX.    The NP R300A mutant expression and purification 
The NP mutant R300A was expressed and purified using similar methods as the NP 
mutant M54A described above. The NP R300A mutant is finally purified by a gel 
filtration column (Fig. 4.35 top), and the protein purity was checked by a SDS-PAGE 
gel (Fig. 4.35 bottom). 12mg of the purified trimeric NP R300A mutant protein was 
obtained from 10 liters of culture. 
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Figure 4.35 The gel filtration chromatograph and the SDS-PAGE gel of the NP R300A 
mutant. 
 
X.    The NP K309A mutant expression and purification 
The NP mutant K309A was expressed and purified using the similar methods as the 
NP mutant M54A described above. The NP K309A mutant is finally purified by a gel 
filtration column (Fig. 4.36 top), and the protein purity was tested by a SDS-PAGE 
gel (Fig. 4.36 bottom). 17mg of the purified trimeric NP K309A mutant protein was 
obtained from 10 liters of culture. 
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Figure 4.36 The gel filtration chromatograph and the SDS-PAGE gel of the NP K309A 
mutant. 
 
XI.    The NP Y319A mutant expression and purification 
The NP mutant Y319A was expressed and purified using similar methods as the NP 
mutant M54A described above. The NP Y319A mutant is finally purified by a gel 
filtration column (Fig. 4.37 top), and the protein purity was tested by a SDS-PAGE 
gel (Fig. 4.37 bottom). 15mg of the purified trimeric NP Y319A mutant protein was 
obtained from 10 liters of culture. 
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Figure 4.37 The gel filtration chromatograph and the SDS-PAGE gel of the NP Y319A 
mutant. 
 
XII.    The NP R323A mutant expression and purification 
The NP mutant R323A was expressed and purified using the similar methods as the 
NP mutant M54A described above. The NP R323A mutant is finally purified by a gel 
filtration column (Fig. 4.38 top), and the protein purity was checked by a SDS-PAGE 
gel (Fig. 4.38 bottom). 17mg of the purified trimeric NP R323A mutant protein was 
obtained from 10 liters of culture. 
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Figure 4.38 The gel filtration chomatograph and the SDS-PAGE gel of the NP R323A 
mutant. 
 
 
4.3.3    The in vivo functional assays of LASV NP N-terminal domain 
To characterize N-terminal domain’s function in viral transcription, a group of 
mutants that resides for the cap binding in N-terminal domain were generated as 
previous described. The NP and the mutant genes were cloned into pCAGGS vector 
and were expressed at a comparable level in mammalian cells (Fig. 4.39a). The LASV 
minigenome assays were performed by transfecting the 293T cells with the in vitro 
transcribed LASV minigenome RNA containing T7-promoter directed LASV 
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s-segment sequence analogue and the Renilla luciferase (RLuc) reporter gene in place 
of NP coding sequence, together with LASV L expression plasmid, LASV WT or 
mutated NP expression plasmid and a β-gal expression plasmid which was used for 
normalizing the transfection efficiency. The increase fold of RLuc activity shows the 
mRNA transcription level of the MG RNA. Comparing to WT NP, the mutants K253A 
and E266A totally lost their function in transcribing MG RNA, whereas the mutants 
W164A, F176A, K309A, Y319A and R323A significantly decrease the activity. The 
mutants W12A, Y209A, Y213A and R300A have minor defect of this activity (Fig. 
4.39b). Taken together, the mutants of the cap binding residues around the deep 
hydrophobic thymidine binding pocket defect viral RNA transcription activity.  
 
Figure 4.39 The role of the residues on the N-terminal deep cavity. a, the NP mutants were 
expressed at the similar levels as the wild type at 15-30 ng plasmid (WT-15, WT-30) in the 
transfected mammalian cells; b, luciferase based LASV minigenome transcription assay for 
WT NP and its mutants. 
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A luciferase based promoter assay for either WT NP or its N-terminal mutants to 
inhibit the Sendai virus induced IFN-β activation was also performed. The result 
shows unlike the mutants of the 3’-5’ exoribonuclease catalytic residues of the C 
terminal domain, these mutants suppress the IFN- β activation as well as WT NP, 
which indicates these residues in the deep cavity of the N-terminal domain do not 
involve in the immune suppression (Fig. 4.40). 
 
 
Figure 4.40 LASV NP mutants of the deep cavity on N-terminal domain are functional in 
suppressing Sendai virus-induced IFN-beta activation.  This result suggests that these 
mutations do not alter the NP structure or affect its IFN suppression activity.  
 
 
 
 
 
 
 138 
 
 
 
 
 
 
 
 
  Chapter 5:  Interaction between LASV NP and  
             Z protein 
 
 
 
 
 
 
 
 
 
 
 
 
 139 
LASV NP protein was reported to interact with Z protein in vivo, and this interaction 
may play an essential role in viral RNA replication and transcription (Eichler, 2004; 
Ortiz-Riaño, 2011). To understand the interaction mechanism, we tried to study the 
interaction in vitro. 
 
5.1    Preparation of Z protein expression construct 
The entire Z gene of Lassa fever virus was from a Z containing pCAGGS plasmid and 
subcloned into a pLOU3 vector, which is a derivative plasmid from pMAL-C2X, 
containing a 6His-tag at the N-terminus of MBP and a Tev proteinase cleavage site 
between the MBP and target protein. The process is the same as the NP gene 
subcloning except both the Z gene fragment and pLOU3 plasmid were treated using 
NcoI and XbaI. The insertion was confirmed by digesting the Z-pLOU3 plasmid with 
NcoI and XbaI and agarose gel electrophoresis. 
 
5.2    LASV Z Protein expression and purification 
The recombinant plasmid was transformed into E.coli expression strain Rosseta cells. 
Single colony was picked for preparation of 500 ml overnight culture. The overnight 
culture was inoculated into 10 liters of the LB medium containing 50 μg/ml Ampcilin 
and 34 μg/ml chloramphenicol and the cells grew at 37°C and 200 r.p.m.. The protein 
was induced by adding isopropyl-beta-d-thiogalactopyranoside (IPTG) to a final 
concentration of 0.1 mM when the OD600 of the cell culture reached at 0.6. Then the 
cell culture was continued to culture at 28°C overnight. 
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The cells were harvested by centrifugation at 8,000 g for 10 min at 4 °C. The cell 
pellet collected from 10L culture was resuspended in 100 ml of 10 mM imidazole 
binding buffer (10%Glycerol, 10mM imidazole, 20mM phosphate pH7.0, 0.3M NaCl) 
with 2 protease inhibitor tablets (Roche), 1 uM DNase (Sigma) and 1 mM 
Phenylmethylsulfonyl fluoride (PMSF) (Sigma). The cells were disrupted by a cell 
disruptor (Constant system Ltd) and centrifuged down at 20,000 rpm for 30 min to 
remove the cell debris. The supernatant was loaded on a Nickel column that was 
equilibrated using the binding buffer. The column then washed with a washing buffer 
(30mM imidazole, 20mM phosphate pH7.0, 0.3M NaCl, 10% glycerol). The fusion 
protein then was eluted with an elution buffer (10%Glycerol, 20mM phosphate pH7.0, 
0.3M NaCl, 0.5M imidazole). The protein buffer was changed into the Tev cleavage 
buffer  (1/50 PBS, 50mM Tris-HCl, 0.5mM EDTA, 1mM DTT, 0.3M NaCl, 10% 
Glycerol) using a desalting column (Hiprep 26/10, GE helathcare). Fractions 
containing HisMBP-Z fusion protein was pooled, MBP tag was cleaved off from the Z 
protein using 1ml His-tagged TEV protease at room temperature overnight. The 
cleaved sample was desalted again to remove the EDTA, and then loaded to the nickel 
resin again to remove the MBP. The flow through sample (Z protein) was 
concentrated to 5 ml and purified by a gel filtration column (Sephacryl S-200, GE 
healthcare) that was equilibrated by the gel filtration buffer (20mM Tris pH 7.5, 0.3M 
NaCl, 10% Glycerol). The protein’s identity and integrity were checked by mass 
spectroscopy and SDS-PAGE. The SDS-PAGEs were carried out using pre-cast 
NuPAGE 4-12% Bis-Tris gels and Powerease 500 according to the manufacturer’s 
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Manuel, with the protein molecular standards of Mark12 (Invitrogen). The 
crystallization trials have been set up. 
 
The expression of Z protein was very successful according to the results shown in the 
SDS gel below (Fig. 5.1). The Z-MBP fusion protein was cleaved by TEV proteinase; 
the upper band is MBP protein and the below one is Z protein.  
 
 
 
 
 
 
 
 
 
 
Figure 5.1 SDS-PAGE gel of Z protein. Lane 1: marker 12; lane 2: flowthrough; lane 3: 30 
mM imidazole wash; lane 4: elution; lane 5: Z-MBP after TEV cleavage. 
 
During gel filtration, Z protein was separated into two, forms which are monomer and 
oligomer. The oligomeric Z protein is brown color while the monomeric Z protein is 
colorless. The oligomeric Z protein was concentrated to 1ml with the concentration of 
6.5 mg/ml, which means an approximate 6.5 mg of oligomeric Z protein was obtained 
from 10-litre culture. The monomeric Z protein was concentrated to 400ul with the 
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concentration of 4.5 mg/ml, which means around 1.8 mg of monomeric Z protein was 
obtained from10-litre culture (Fig. 5.2 & 5.3). 
 
 
 
 
 
 
 
 
Figure 5.2 The SDS-PAGE gel of gel filtration. Line 1: marker 12, line 2-8: oligomeric Z 
protein- the first peak shown in figure 17, line 9-11: MBP protein-the second peak in figure 
17, line 12-15: monomeric Z protein- the third peak. 
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Figure 5.3 The gel filtration graph of the Z protein. The first peak is oligomeric Z 
protein and the third peak is monomeric Z protein. The second peak is MBP. 
 
After gel filtration, the monomeric Z protein was quite pure, but the oligomer Z 
protein needs further purification. So the oligomeric Z protein was then go through 
the nickel column again. Some of the contamination proteins were removed, which 
directly go through the nickel column. The oligomeric Z protein was bound on the 
nickel column and was eluted with 10 mM imidazole buffer containing 20 mM tris 
pH7.5, 0.3 M NaCl and 10% glycerol. As shown in figure 5.4, lane 5, there is still an 
extra band. They may be some contaminant proteins which are bound inside the Z 
oligomers.  
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Figure 5.4 SDS-PAGE gel of purified Z protein. Lane 1: marker 12, Lane 2-3: monomeric 
Z protein, lane 4: flowthrough after nickel column, lane 5: elute with 10 imidazole buffer. 
 
5.3    Characterization of LASV Z protein 
To determine the molecular weight of different forms of Z protein, a gel filtration 
chromatography was performed using a Superdex 200 10/300 GL column (GE 
healthcare) and a running buffer containing 20mM Tris pH 7.5, 0.3M NaCl and 10% 
glycerol. The molecular weight of the monomeric and oligomeric Z was determined 
based on the protein elution volumes against the molecular standards. The monomeric 
Z appeared six peaks during the gel filtration (Fig. 5.5). indicating that monomeric Z 
protein can form different oligomers. 
 
 As described in chapter for LASV NP protein, we use the same equation y= 
-0.5764x + 19.336 to calculate the size of oligomer Z protein. According to the elution 
volumes and the molecular weight of each protein, monomeric Z protein was obtained 
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from figure 5.5. The monomeric Z protein formed different peaks in the gel filtration, 
indicating that the monomer can form oligomers. In the monomeric peak positions, 
there are three peaks, which may caused by the monomers with different sizes of 
RNA bound. 
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Figure 5.5 The purified monomeric Z protein from gel filtration by Superdex 200 10/300. 
Six peaks were formed, corresponding to different Z protein oligomers. 
 
The elution volume of oligomeric Z is 12.3ml (Fig. 5.6), so the size of oligomeric Z 
protein is around 212 kDa. Because the monomeric Z protein is 11 kDa, so it was 
assumed about 20 monomers form the oligomeric Z protein. 
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Figure 5.6 The purified oligomeric Z protein from gel filtration by Superdex 200. 
 
5.4    Interaction between NP and Z protein 
In order to test whether NP protein and Z protein have interaction in vitro, the 
Isothermal titration calorimetry (ITC) experiment was performed using VP-ITC 
microcalorimeter (MicroCal). 2ml of 3.75mg/ml NP protein and 450μl of 3.25mg/ml 
Z oligomer protein were loaded into VP-ITC with both proteins in same buffer 
containing 20 mM Tris pH7.5, 0.3 M NaCl and 10% glycerol. During the experiment, 
the ligand (Z protein) was titrated into the sample cell (NP protein) in precisely 
known aliquots (10 ul). The data were recorded and fitted using the Origin software 
(Fig. 5.7). In the figure, the K is binding constant and N is binding stoichiometry, 
while ΔS is entropy changes, and ΔH is enthalpy changes and ΔG is Gibbs energy 
changes.  
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Their relationship can be describe as: 
ΔG=-RTlnK=ΔH-TΔS (R: gas constant; T: absolute temperature) 
The binding constant is 3.11 × 10
-5 
M. Interestingly, we also determined the 
interaction between monomeric Z protein and NP protein using the VP-ITC and the 
result showed that there is no interaction between the NP and the monomeric Z 
protein. 
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Figure 5.7 The ITC result of NP and oligomeric Z protein interaction. 
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6.1    The immune evasion function of LASV NP 
Human cells have different receptors to detect viral infections and trigger different 
pathways to control the viral infections. To produce interferons is the first line for 
human immune system to attack viral infection. In the same time, viruses have 
developed different strategies to evade the host immune responses. By determination 
of the Lassa fever virus nucleoprotein structure and in vitro and in vivo assays, we are 
the first group in the world to discover that arenaviruses use 3’-5’ exoribonuclease to 
suppress the human immune responses. 
 
3’-5’ exonucleases are a big family enzymes, which involve in many crucial processes 
in cells, such as the RNA maturation, DNA replication and DNA and RNA 
degradation. Trex1 is a human 3’-5’ exonuclease, which is crucial for degrading 
DNAs during cell apoptosis or cell death, and genetic data and biochemical data 
showed that natural mutation of the Trex1 resulted in inactivation of the enzyme 
would lead to autoimmune disease (Yang, 2007; Stetson, 2008). As the structure of the 
C-terminus of the LASV NP is very similar to human Trex1, we proposed that the 
LASV NP can remove viral pathogen-associated pattern molecule RNAs, so that the 
human receptors RIG-I and MDA5 can’t detect the viral infection and therefore no 
interferon production, It has evidences to show that the ligands for RIG-I and MDA5 
are short triphophated dsRNA and long dsRNA, respectively. Our unpublished data 
showed that the NP could selectively recognize dsRNA and cleave the dsRNA much 
quicker than ssRNA. In the structure of C terminal domain of LASV NP protein, we 
identified that catalytic residues are D389, E391, D466, D533 and H528 which 
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belongs to DEDDh subfamily of exonucleases (Fig. 6.1). Exonucleases are known as 
two metal dependent enzymes (Steitz, 1993). However, from our structure studies, 
only one Mn
2+
 molecule is found in the LASV NP. A 3’-5’ exonuclease, E.coli DNA 
polymerase was reported only one divalent cation molecule was found in the native 
complex, but the second metal molecule was found in the product analogy dNMP 
complex (Xia, 2012). We therefore proposed that the second Mn
2+
 molecule could be 
seen in the structure if the substrate bound on the NP. 
 
Zinc finger fold is crucial for recognizing and binding DNA or RNA, and Zinc finger 
nucleases have been used as a specific tool for gene therapies (Urnoy, 2005). There is 
a zinc binding site near the active site of the LASV NP, which may play essential role 
in recognizing the dsRNA molecules. The purifications of the four mutant proteins of 
zinc binding site showed that their expression level in E.coli are very low (Fig. 4.21- 
4.24), which indicates that the residues around zinc ion may be critical for protein 
folding and stabilization of the structure and/or contribute to the substrate binding and 
specificity of the exoribonuclease activity. 
 
The NP Tacaribe virus was reported to have no immune suppression function 
(Martínez-Sobrido, 2007; Lan, 2008), but our recently unpublished data shows that 
the NP of Tacaribe virus has the similar activity as the LASV NP in degrading dsRNA 
and ssRNA in vitro, and in vivo assays shows that the Tacaribe virus has the similar 
interferon suppression function as the LASV NP, which means that all the 
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arenaviruses known share the same function in immune suppression. 
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Figure 6.1 C-terminal domain of NP protein that holds the exoribonulcease activity site 
is strucuturally similar with many DEDDh exonucleases such as Trex1 and DNA 
polymerase III ε chain. a, five amino acids D389, E391, D466, H528 and D533 reside at the 
catalytic site, amino acids E399, C506, H509 and C529 reside around the Zn
2+ 
finger fold 
motif; b, the electrostatics map of NP C-terminal domain, human Trex 1 (PDB code: 2IOC) 
and DNA polymerase III ε chain (PDB code:1J54) all present a negatively charged (colored in 
red) center. 
 
6.2    The cap-binding cavity on LASV NP 
The cap structure on 5’ end of mRNA is essential for protein translation, it protects the 
mRNA from being degrading by 5’ exonucleases. Unlike non-segmented group of 
negative strand RNA virus that the L protein has the capping activity, the segmented 
negative strand RNA viruses have to steal cap from the host cellular mRNA. The most 
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well established cap snatching model in segmented negative strand RNA virus is the 
heterotrimeric polymerase complex of influenza A virus which is consist of PA, PB1 
and PB2, where the cap binding site is on PB2. But unlike the polymerase complex, 
the arenaviruses genomic RNA only encodes four proteins. The glycoprotein forms 
the spike on the surface to interact with host cell membrane, Z protein function as the 
matrix protein, that makes the cap binding site can only be located on NP or L protein. 
L protein is a RNA dependent RNA polymerase (RdRp) that contains three functional 
domains, the middle one is the RdRp, the N terminal domain is an endonuclease 
which is similar to PA subunit in influenza A virus. There is only one domain structure 
left uncharacterized and we don’t know whether it is the cap-binding domain.  
 
Although the N-terminal domain of LASV NP is structurally unlike any of the cap 
binding proteins, the hydrophobic thymidine-binding pocket that consist of F176, 
W164, L172, M54, L120, L239 and I241 shares common features with other cap 
binding protein such as PB2 in influenza A virus, the cap binding protein (CBC), the 
eukaryotic translation initiation factor (eIF4E) and the vaccinia viral protein 39 (VP39) 
(Fechter, 2005; Guilligay, 2008). The significant features of the cap binding protein is 
that there is an aromatic sandwich shape that the aromatic ring of the m
7
G is anchored 
in the middle of two protein aromatic residues (F404/H357 in PB2, W102/W56 in 
eIF4E, Y20/Y43 in CBC and Y22/F180 in VP39), and there is at least one conserved 
negatively charged acidic amino acid (E361 in PB2) since the purine ring that 
contains the methylated N7 is positively charged and the m
7
G counteracts with acidic 
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residues Glu or Asp on the protein, plus there is a general area for binding the 
triphosphate group (Fechter, 2005). In N-terminal domain of NP, residues K253, R300, 
K309 and R323 are involved in anchoring the triphosphate group (colored in orange 
in Fig.59) of dTTP, whereas the acidic residue E117 that is assumed to counteract 
with the methylated N7 on the m
7
G is located at the deep end of the cavity. But unlike 
the typical aromatic sandwhich shape in cap binding protein, only amino acid F176 is 
found to horizonally align with the aromatic ring on dTTP (Fig. 6.2). This unique 
aromatic architecture may require residue W614 to change conformation to 
accommodate the m
7
G. 
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Figure 6.2 N-terminal domain of NP in complex with cap analog dTTP. Residues that 
anchor the triphosphate group are colored in yellow, residues that form the hydrophobic 
cavity are colored mainly in blue, the acidic residue E117 is colored in green. 
 
Since influenza A virus and Lassa virus are both belong to the segmented negative 
strand RNA virus, comparing the cap binding protein PB2 and NP of these two virus 
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will be present below (Fig. 6.3). The residues that are located at the hydrophobic 
cavity of PB2 on influenza A virus are F323, F325, F330, F404 and F363. Residues 
Phe404 and H357 forms the top and the bottom of the aromatic sandwich, whereas 
acidic residues E361 is also present at the same cavity.  
 
           
E361	
F404	
H357	
 
Figure 6.3 PB2 subunit of influenza A virus in complex with m
7
GTP. The acidic residue 
E361 is colored in red, and the residues that form the sandwhich architecture are colored in 
magentas. 
 
The triphosphate group can be observed from both the dTTP and UTP complex 
electron density map that has been described in last chapter. Along with a second 
hydrophobic cavity at the entrance, where a base recognizing residue E266 was found, 
the whole cavity within the center of N-terminal domain of NP is considered to be the 
entire m
7
GpppN cap structure binding site which shares the common feature with 
other typical cap binding protein. The in vivo experiments were set to characterize the 
viral transcription function of NP by using the LASV minigenome replicon assay. The 
Renilla luciferase activity presents the LASV MG mRNA expression level with 
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participation of wild type NP and various mutants that substitute single amino acid on 
cap binding site with alanine. The various degree of defect on MG mRNA 
transcription shows the critical role of these residues that reside around the 
hydrophobic cap binding cavity in viral genomic RNA transcription. Both the 
structural and the functional result are consistent of the hypothesis of NP’s role in cap 
snatching mechanism in Arenaviridae family. Of course, further studies are required 
to further characterize the cap binding function, such as to test the NP binding affinity 
to m
7
GpppG and to have complex structure of the NP in complex with m
7
GpppG. 
 
6.3    Update of the recently discovered NP-RNA complex 
The Saphire’s research group in Scripps institute recently solved the structure of N 
domain of LASV NP and RNA complex (Hastie, 2011) (Fig. 6.4). This complex 
structure reveals a gating mechanism for RNA binding with NP. The structure of N 
terminal domain of NP binds to a random RNA from the expression host E.coli cell 
while the whole length of NP protein can’t be crystallized with RNA. The difference 
between our model and the complex is that helix α5 and α6 will change conformation 
to open a gate for RNA to bind within the center cavity. The β2 which is formed by 
residues V24 and Y25 sits between α5 and α6 in our structural model, but in the 
NP-RNA complex model (Hastie, 2011) α5 and α6 are widely open, and the residues 
between them are absent.  After RNA binding to NP, a linear form of NP binding 
with RNA will take place of the trimeric NP. Although more experimental evidences 
need to be provided, this complex structure offers a possible way for NP 
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encapsidating the viral genomic RNA.  
 
 
Figure 6.4 The comparision between native structure of NP N domain and NP-RNA 
complex. The native NP is colored in grey while the complex is colored in blue (Figure from 
Saphire, 2011). 
 
 
 
6.4    Interactions between NP and other arenaviral proteins 
After solving the structure of LASV NP protein, it becomes our interest to know 
whether and how NP interacts with other arenaviral proteins. The matrix LASV Z 
protein has been reported to be sufficient for mature virion budding and can modulate 
the activity of vRNP by interact with NP protein (Strecker, 2003; Capul, 2011). The in 
vitro assay ITC result showed that there is interaction between LASV NP and 
oligomeric Z protein (described in chapter 5). The recently published study in 
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Ortiz-Riaño’s group also pointed out the residues on LCMV NP that are involved in 
type I IFN suppression overlap with the residues that play critical role in NP-Z 
interaction, and the mutation study showed these two functions are independently 
carried out (Ortiz-Riaño, 2011). 
 
L protein of arenaviruses contains a middle RdRp domain and an endonuclease 
domain on its N terminal side. Although there has been studies on the interaction 
between NP and RdRp L protein, like the report on residue 53 and C-terminal domain 
of LMCV NP are critical for LMCV L protein’s function during replication and 
transcription (Kerber, 2011), how did they interact to each other and the interaction’s 
role in transcription remains unclear. In the future, the detailed structural information 
of the NP-L complex may provide more evidence in arenaviruses replication and 
transcription mechanism.  
 
6.5    Conclusion and future work 
Both the structural and functional studies provide evidences that 3’-5’ 
exoribonuclease activity in C terminal domain of Lassa nucleoprotein performs 
suppression of type I IFN-β induction. This is the first nucleoprotein structure in 
arenaviruses, the IFN suppression function shield the light in how arenaviruses escape 
from the host innate immune system, our research suggests that NP plays a critical 
role in suppressing IFN by removing PAMP RNA ligands specifically. The potential 
cap binding site on N terminal domain of LASV NP explains the cap snatching 
mechanism of arenaviruses during viral genome transcription, this cap snatching 
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mechanism that is shared in segmented negative strands RNA viruses provide 
transcriptional evidence in evolution of negative strand RNA virus. Along with the 
typical zinc finger ring fold on C terminal domain, these findings reveal many 
potential drug target based on the NP structure model that can be used not only in 
designing vaccine to combat with arenaviruses but also provide structural evidence 
for studies on other negative strand RNA viruses.  
 
The quaternary centrosymmetric structure of LASV NP in solution was then obtained 
and confirmed by small-angle x-ray scattering (SAXS) and cryo-electron microscopy 
(cryo-EM) by Brunotte’s group (Brunotte L, 2011). Although the N terminal domain 
of NP with host random RNA complex was solved, the way of NP encapsidating viral 
genomic RNA is not clear in details. The question of what specific RNA binding with 
NP to form the RNP complex need be studied in the further work. Taken together, 
these findings may provide us very good target for design drug.  
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Appendix I 
 
I.1    Diagram of LASV virion components. 
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I.2    Plasmid constrcution: vector pLou3 
Both LASV NP and Z protein were ligated on pLou3 vector that contains the 6His-tag 
site at the N terminus of maltose binding protein (MBP) with the tev cleavage site 
between the target gene and MBP gene. 
 
 
1
pLou3
6706bp
lacI
malE
lacZ
q
bla
M13 ori
ori
rop
Ptac
Tev site
XbaI (2767)
PstI (2783)
SalI (2773)
6 x His
PmlI (2751)
EcoRI (2755)
BamHI (2761)
SacI (2680)
HindIII (2787)
ApaI (642)
SwaI (4437)
BglII (1929)
Bpu1102I (2356)
BsmI (2190)
BstEII (612)
DraIII (4662)
Eam1105I (4265)
Tth111I (5864)
Eco56I (4763)
EcoRV (881)
HpaI (937)
MluI (431)MscI (6681)
NaeI (4765)
NdeI (1526)
PflMI (13)
SapI (5765)
ScaI (3784)
SplI (1860)
NdeI (1568)
AvaI (2717)
NcoI (2741)
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I.3    Forward and reverse primers of the mutants 
 
Mutants F/R primers   Primer sequences     
M54 Forward AACGGTTG  GCG  CGCAAGGAGAGAAGGGATGACAATGATTTGAAAC 
 Reverse TCCTTGCG  CGC  CAACCGTTGAACATTACTGACTTCGGAGAAGTC 
E117 Forward TCAGAACA  GCA  AGGCCATTAAGTGCAGGTGTCTATATGGGCAAC 
 Reverse TAATGGCCT  TGC  TGTTCTGATCACCTTTGACTTTAACTTCTCTAG 
L120 Forward AAAGGCCA  GCA  AGTGCAGGTGTCTATATGGGCAACCTAAGCTC 
 Reverse CCTGCACT  TGC  TGGCCTTTCTGTTCTGATCACCTTTGACTTTAAC 
W164 Forward GTGAGAGTT  GCG  GATGTGAA;AAATGCAGAGTTGCTCAATAATCAG 
 Reverse TTCACATC  CGC  AACTCTCAC;CACTCCATCTCTCCCAGCCCGAG 
F176 Forward ATAATCAG  GCC  GGGACCA;TGCCAAGTCTGACACTGGCATGTC 
 Reverse TGGTCCC   GGC   CTGATTAT;TGAGCAACTCTGCATTTTTCACATC 
Y209 Forward GATTTGGGTTTGATC  GCC  ACAGCAAAGTATCCCAAC  
 Reverse GATACTTTGCTGT  GGC  GATCAAACCCAAATCTGTC  
Y213 Forward GATCTACACAGCAAAG GCT  CCCAACACTTCAGACTTAG  
 Reverse CTGAAGTGTTGGG   AGC  CTTTGCTGTGTAGATCAAAC  
K253 Forward GGTGCAGCTGTG  GCG  GCAGGAGCTTGCATGC  
 Reverse GAAGCTCCTGC   CGC   CACAGCTGCACCCAAGC  
E266 Forward GGCAATATGTTG  GCG  ACAATCAAGGTGTCAC  
 Reverse CACCTTGATTGT  CGC  CAACATATTGCCACCATC  
R300 Forward CTGGTGAA  GCG AATCCTTATGAAAACATACTCTACAAGATTTGTTTG 
 Reverse ATAAGGATT  CGC  TTCACCAGGGGTGTCTGAAATGAACATTCCAAG 
K309 Forward ATACTCTAC  GCG  ATTTGTTTGTCAGGAGATGGATGGCCATATATTG 
 Reverse CAAACAAAT  CGC  GTAGAGTATGTTTTCATAAGGATTCCTTTCACCAG 
Y319 Forward GATGGATGGCCA   GCT  ATTGCATCAAGAACCTC  
 Reverse TCTTGATGCAAT   AGC   TGGCCATCCATCTCCTG  
R323 Forward ATTGCATCA  GCA  ACCTCAATAACAGGAAGGGCCTGGGAAAACACTG 
 Reverse TATTGAGGT  TGC  TGATGCAATATATGGCCATCCATCTCCTGACAAAC 
D389 Forward GACCTGGATG GCC ATTGAAGGAAGACCTG   
 Reverse CTTCCTTCAAT GGC CATCCAGGTCTTAGC   
E391 Forward GGATGGACATT  GCA  GGAAGACCTGAAGATC  
 Reverse CAGGTCTTCC TGC AATGTCCATCCAGGTC   
G392 Forward GACATTGAA   GCA  AGACCTGA  AGATCCAGTGGAAATTGCCCTCTA     
 Reverse TCAGGTCTTGCTTCAATGTCCATCCAGGTCTTAGCATTTGGGTC  
E399 Forward GATCCAGTG GCA ATTGCCC TCTATCAACCAAGTTCAGGCTGCTA  
 Reverse GGGCAATTGC CACTGGATC TTCAGGTCTTC CTTCAATGTCCATC 
D466 Forward GGGGTCCGAT GCC ATAAGGAAACTCCTTG   
 Reverse GAGTTTCCTTAT  GGC  ATCGGACCCCTGACAG  
C506 Forward AAAGACTTA GCC CACATGCA CACAGGTGTCGTTGTTGAAAAGAAG  
 Reverse TGCATGTGGC ATAAGTCTTT ATACTGGTCC CAGACTGCAT TTTCA  
H509 Forward GCCACATG  GCC  ACAGGTGT CGTTGTTGAAAAGAAGAAAAGAGGC 
 Reverse ACACCTGTGGCCATGTGGC ATAAGTCTTTATACTGGTCCCAGAC 
H528 Forward TAACCCCT  GCC  TGTGCACT AATGGACTGCATCATGTTTGATGCA    
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 Reverse AGTGCACAGG  CAGGGGTTA  TTTCCTCTTTACCGCCTCTTTTCTT 
C529 Forward CCCCTCAC GCT GCACTAAT GGACTGCATCATGTTTGATGCAGCA  
 Reverse ATTAGTGCAG CGTGAGGGG TTATTTCCTCT TTACCGCCTCTTTTC  
D533 Forward ACTAATG GCC TGCATCATGT TTGATGCAGCAGTGTCAGGA  
  Reverse ACATGATGCA GGCCATTAGT GCACAGTGAGGGGTTATTTCCTCT  
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I.4    In vitro ssRNA synthesis 
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I.5    In vitro dsRNA synthesis 
 
      dsRNA              Synthesized by ssRNA 
5'-OH/5’-OH dsRNA 30nt cRNA (Chem); 30nt vRNA (Chem) 
5'ppp/5'ppp dsRNA 5'ppp cRNA (Bio); 5'ppp vRNA (Bio)   
5'ppp/5'-OH dsRNA 32nt 5'ppp vRNA (Bio); 30nt 5'-OH cRNA (Chem) 
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